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 Abstract  
 
Psoriasis is a chronic inflammatory skin disorder affecting around 4 % of the world 
population. Psoriasis develops upon exposure to an unknown antigen in a genetically 
susceptible individual due to dysregulated innate and adaptive immune responses. 
Mannose binding lectin (MBL), an innate immune player, is an immune response 
modulator through its effect on Toll like receptors (TLRs) of monocytes and dendritic 
cells, both are activated early during psoriasis development. In this study, we investigated 
the efficacy of MBL treatment in Imiquimod psoriasis animal model and the involved 
molecules in the observed response. The induction and treatment were evaluated 
clinically, dermoscopically, histopathologically and Interleukin (IL)-6 & IL-12 
expression level using quantitative real time polymerase chain reaction (qPCR). Psoriasis 
was successfully induced in C57Bl mice using Imiquimod. The successfully induced 
psoriasis improved significantly on MBL treatment (P < 0.05). On the other hand, the 
control group didn’t show any significant improvement (P> 0.05). IL-6 expression level 
was reduced to normal on MBL treatment while it was significantly higher in PBS (P > 
0.05). IL 12 was slightly lower in MBL treated group than both normal and PBS group 
but wasn’t statistically significant (P>0.05). These results support a role for MBL in the 
treatment of psoriasis through lowering IL-6 level and potentially IL-12. Both cytokines 
are involved in early psoriasis development with establishment of T helper (Th) 17 & 
Th1 pathways, respectively. We recommend further investigation of MBL as a promising 
therapeutic of psoriasis in other psoriasis mouse models and in clinical trials. 
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Introduction 
Psoriasis is an inflammatory skin disease affecting 3 - 4% of world population. 
Psoriasis can be disfiguring and disabling in severe cases. The disease affects 
patients’ psychology and their life quality. Moreover, psoriasis has been recently 
associated with other comorbidities as diabetes, cardiovascular risk, and other 
elements of metabolic syndrome (Cai et al., 2013; Griffiths and Barker, 2010; 
Mahil et al., 2016). 
In 2014’s Sixty-seventh World Health Assembly of the World Health Organization 
(WHO) a resolution on psoriasis was passed. All state members have committed to 
increase the awareness about the disease and to fight stigmatization associated with it. 
WHO recognized that psoriatic patients suffered needlessly across the globe 
inadequate treatment options among other causes. With the upward trend psoriasis 
incidence and prevalence seems to follow, the high global burden the disease, 
according to WHO, equals twice as acute hepatitis C, there is flare in psoriasis 
therapeutic market (World Health Organization [WHO], 2016). It is expected that 
the psoriasis market grow from $5 B market in 2014 to $13.3 B in 2024. 
The exact cause of psoriasis is still unknown; however there is evident 
dysregulated immune response in genetically susceptible individuals to unknown 
stimuli (Mahil et al., 2016; Mitra et al., 2013). 
Innate and adaptive immune responses show dysregulation in psoriasis patients. Of 
the innate immune system key players, both mannose binding lectin (MBL) and toll 
like receptors (TLRs) have been linked to psoriasis (Hari et al., 2010; Heitzeneder et 
al., 2012). MBL is an inflammatory response modulator and is linked to autoimmune 
diseases e.g. systemic lupus erythematosus, rheumatic fever (Heitzeneder et al., 
2012). MBL has a protective role against extensive unneeded inflammatory reaction 
leading to tissue damage as occurs in psoriasis pathogenesis (Downing et al., 2005; 
Wang et al., 2011a). MBL levels and function depend on its gene mbl2.  It has 6 
polymorphisms in the promoter and exon 1 regions leading to varying degrees of loss 
of MBL function (Heitzeneder et al., 2012). The B variant of mbl gene has been 
associated with psoriasis in Turkish population (Turan et al., 2014). 
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Effective treatment of psoriasis needs to consider attacking a central, early point in 
the psoriasis development pathway without compromising the immunity to avoid the 
major side effects of the biologic therapy available today. MBL replacement restores 
the normal tolerance of the skin lost during psoriasis without impairing the immune 
response to infection or malignant transformation.  
The aim of this work was to evaluate the efficacy of MBL, as an immune response 
modulator, in the treatment of psoriasiform inflammation induced in mice as an 
animal model for psoriasis.  
 	  
	   Review of Literature 	  
	   	  
3 	  
Review of Literature 
Psoriasis is a chronic proliferative skin condition (Griffiths and Barker, 2010). It 
is a common disease affecting about 3 – 4 % of world's population (Cai et al., 2013). 
The condition is disfiguring and affects patient's quality of life (Pollock et al., 2011). 
Epidemiological studies showed that both sexes are equally affected by psoriasis. 
It usually first develops around 20 years old or sixth decade of life. Type I psoriasis 
begins before age 40 and represents about 75% of all psoriasis patients. Type I 
patients usually suffer more severe course, with limited success of treatment, 
increased prevalence of specific human leucocyte antigen (HLA)-types and stronger 
hereditary ties (Mitra et al., 2013; Sabat et al., 2007). 
Furthermore, a distinct group of disorders have been identified by some 
epidemiological studies to frequently associate with psoriasis, including colitis, 
rheumatoid arthritis, diabetes, metabolic syndrome and hypertension (Sabat et al., 
2007). 
Psoriasis has different clinical subtypes with plaque psoriasis, the most common 
variant affecting almost 80-90% of cases. Typically lesions are well-demarcated red 
scaly plaques with characteristic salmon pink color and white silvery scale the 
distribution is usually on the extensor surface of the limbs and the sacral area, (Figure 
1) (Burden and Kirby, 2016). Other clinical types include pustular, erythrodermic, 
unstable psoriasis and guttate psoriasis (Burden and Kirby, 2016; Sticherling, 
2005).  
Psoriasis may also affect specific sites e.g. psoriasis of the scalp, nail psoriasis, 
flexural, genital psoriasis and palmoplantar psoriasis. Psoriasis of pregnancy 
(dermatitis herpitiformis) is a specific entity affecting pregnant females either arises 
in a known psoriatic patient or de novo during pregnancy, and it can be associated 
with placental insufficiency. Psoriatic arthropathy is an oligoarticular seronegative 
arthropathy, which affects both axial and peripheral joints along with soft tissue 
swellings. It may or may not be associated with cutaneous lesions and it affects 30 % 
of patients with cutaneous psoriasis (Ariza et al., 2013; Hébert et al., 2012). 
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Microscopically (Figure 2) psoriasis is composed of three distinct components; 
the epidermal component, the vascular component and the inflammatory component 
(Sticherling, 2005). Psoriatic lesions exhibit epidermal acanthosis (diffuse epidermal 
hyperplasia) with elongation of rete ridges, parakeratosis (retention of the nuclei in 
stratum corneum) along with lymphocytic infiltration with loss of granular cell layer. 
The dermal papillae shows dilated elongated and tortuous blood vessels along with 
inflammatory infiltrate with predominant T cell population, neutrophils and dendritic 
cells (Burden and Kirby; 2016; Cai et al., 2013; Lever & Elder, 2009).    
 
 
 
 
 
 
Figure 1: Plaque Psoriasis. Red salmon pink well demarcated plaque on 
the extensor surface of the arm covered with white silvery scale. 
Adopted from Burden and Kirby, 2016 
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Despite the knowledge gathered regarding the molecular mechanisms behind 
psoriasis, major questions are still asked. Is the primary nature of psoriasis is 
keratinocyte disorder or an immunologic one? Is the disease autoimmune in nature or 
auto-inflammatory or both? Is it systemic or cutaneous disorder with comorbidities?  
Which has the upper hand regarding disease initiation, progression and therapeutic 
response the environmental or the genetic factors? (Nestle et al., 2009). 
  
Figure 2: Psoriasis Pathology. A) Early Papillary dermal vasodilatation and edema 
with leukocyte infiltration followed by epidermal changes in the form of thinning of 
the granular layer along with mild epidermal hyperplasia, scattered parakeratosis, 
and in the lower half of the epidermis leukocytic infiltration within foci of 
spongiosis with formation of Spongiform Pustule of Kogoj. B) Fully developed 
plaque psoriasis with more evident parakeratosis with focal orthokeratosis, Munro 
micro-abscesses formation (accumulation of neutrophils in the stratum corneum), 
near absence of the granular layer, marked hyperplasia with elongation of rete ridges 
and supra-papillary epidermal thinning giving the characteristic club shaped, 
branched and sometimes fused at bases rete ridges. Mononuclear leukocyte 
infiltrates in the lower part of the epidermis are still evident.  Adopted From Lever 
& Elder, 2009. 
A	   B	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ETIOPATHOGENESIS OF PSORIASIS 
Psoriasis is multifactorial in nature with no obvious single etiology. With the 
contribution (Figure 3) of genetic background, environmental and endogenous factors 
clinical psoriasis develops (Mahil et al., 2016; Sticherling, 2005). 
The paradigm of psoriasis etiopathogenesis has evolved from divine power in 
ancient records passing through unknown infectious organism to a pure keratinocyte 
proliferation disorder and finally as a dysregulated immune system mediated disease 
(Mitra et al., 2013).  
 
 
 
I. Genetics of psoriasis: 
The genetic background is well-recognized in psoriasis (Figure 3), however it has 
to be triggered by environmental factors for psoriasis to develop (Brotas et al., 2012; 
Sticherling, 2005). 
The prevalence of psoriasis is much greater among 1st and 2nd degree relatives than 
healthy controls. Also the susceptibility to develop psoriasis is 14% if one parent is 
psoriatic, elevated to 41% if both are, and drops to 6% if one sibling is affected 
compared to only 2% if there is no family history of psoriasis. The concordance rate 
Figure 3: Etiopathogenesis of Psoriasis. Psoriasis is considered to develop due 
to co-occurrence of inflammatory dysregulation, keratinocyte dysfunction and 
vascular dysfunction on a genetic basis in response to environmental initiating 
stimuli eventually resulting in epidermal & vascular hyperplasia along with 
dermal and epidermal inflammation.  Adopted from Sticherling, 2005.  
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in twins ranges from 64% to 73% in monozygotic twins and 15% to 20% in dizygotic 
twins (Griffiths and Barker, 2010; Nestle et al., 2009). Moreover, in monozygotic 
twins, when both siblings develop psoriasis, the distribution, severity and age of onset 
are similar which illustrates the role of genetics (Nestle et al., 2009).  
Genome Wide Association Studies (GWAS) highlighted the association of 20 
different loci with psoriasis development (Hébert et al., 2012; Stuart et al., 2012). 
Of these genes, endoplasmic reticulum aminopeptidase 1 (ERAP1) gene highlighted 
the importance of innate immune system in the pathogenesis of psoriasis. ERAP1gene 
encodes for aminopeptidase regulating the peptide ligands of MHC- class I encoded 
by HLA-C (Strange et al., 2010; Hébert et al., 2012). Moreover, GWAS attracted 
the attention to the Th17/ IL23 key role in psoriasis. Polymorphisms of genes 
involved in regulating this pathway as IL12B, IL23R (PSORS 7) and IL23A have been 
associated with psoriasis (Hébert et al., 2012). Other genes - identified by GWAS- 
defined the important role of nuclear factor kappa (NFкB) pathway in psoriasis 
development e.g. Tumor Necrosis Factor Alpha-induced protein 3 (TNFAIP3), TNIP1 
(TNFAIP3- interacting protein 1), reticuloendotheliosis viral oncogene homolog (v-
rel), tyrosine kinase 2 (TYK2), TRAF3-interacting protein 2 (TRAF3IP2) and nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha (NFKBIA) 
(Hébert et al., 2012).   
Mannose-binding lectin (mbl) gene polymorphism analysis in psoriatic patients 
showed increased prevalence of B variant in psoriasis patients compared to healthy 
control subjects (Turan et al., 2014). mbl gene encodes for MBL a pattern 
recognition molecule with inhibitory effects on TLR 4 & TLR9. 
II. Environmental factors: 
As stated before psoriasis develops in a genetically susceptible individual on 
exposure to certain environmental conditions that trigger dysregulated innate immune 
response (Mahil et al., 2016; Sticherling, 2005). The environmental factors accused 
in psoriasis development range from infection, trauma to psychogenic factors, 
cigarette smoking, excessive alcohol use and sunlight exposure (Burden and Kirby, 
2016).  
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GWAS highlighted the role of the environment and the microbiome in psoriasis 
pathogenesis. For example, the discovery of the association of 3 susceptibility 
variants in late cornified envelope (LCE) gene cluster; LCE3A, LCE3C and LCE3D 
with psoriasis highlighted the role of skin barrier in disease development (Hébert et 
al., 2012). Another GWAS discovered the association of psoriasis with high copy 
number of beta-defensin genes on chromosome 8. β defensins are peptides with 
antimicrobial activity expressed in epidermis to guard against microorganisms and are 
highly expressed in psoriatic plaques. This high level of β defensins with their 
cytokine-like properties may precipitate an inappropriate inflammatory response after 
minor skin injury, infection or other environmental trigger leading to clinical psoriasis 
(Hollox et al., 2008; Hébert et al., 2012). Moreover, interferon induced with helicase 
C domain 1(IFIH1) gene polymorphism has been shown to be associated with 
psoriasis. IFIH1 encodes for pattern recognition receptor plays a key role in sensing 
viral infection and subsequent activation of a cascade of antiviral responses including 
type I interferons and pro-inflammatory cytokines induction (Strange et al., 2010; 
Hébert et al., 2012).  
a. Infection: 
Infection has been identified as a trigger for psoriasis vulgaris development and 
exacerbation along with the guttate variant (Sticherling, 2005). β hemolytic 
streptococcal infection and α streptococci have been accused in the development and 
exacerbation of different types of psoriasis (Sigurdardottir et al., 2013). 
Two models are proposed trying to explain the role of infection in the pathogenesis 
of psoriasis. 1st model suggests cross reactivity between antigens of streptococci and 
epidermal keratinocytes. Thus, on exposure to infection primed T cells attack self-
epidermal keratinocytes starting chronic inflammatory response. The 2nd model 
increments streptococcal super-antigens which bridge HLA-antigen and T-cell 
receptor without the presence of specific antigens within the receptor complex and 
subsequently activate polyclonal T-cells and induce massive cytokine release with 
subsequent immunological processes (Sticherling, 2005; Sigurdardottir et al., 
2013).    
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b. Psychological factors: 
Stress is a proven provocateur of psoriasis development or exacerbation of active 
disease. 60% of psoriatic patients mentioned stresses to be associated with 
development of psoriasis and /or its exacerbation. Furthermore, stress management 
programs shorten the time needed to achieve clearance with standard therapies 
(Griffiths and Barker, 2010; Sticherling, 2005). 
 Recent advances in neuro-immunology relate psychological and neurological 
processes to immunological ones (Sticherling, 2005). Furthermore, pathologically 
worrier psoriatic patients have less response to photo therapy (Griffiths and Barker, 
2010).   
koebner phenomenon in psoriasis can be seen in this prospective; trauma as 
mechanical stress inducing psoriasis within days to weeks (Sticherling, 2005) 
III. Immunity & psoriasis: 
Immune cells have been introduced as players in the pathogenesis of psoriasis to 
complement the soul keratinocyte proliferative disorder as the primary pathogenesis 
of psoriasis (Burden and Kirby, 2016). The evidence is compelling, specifically, the 
increased numbers of immune cells, specifically dendritic and T cells, in psoriatic 
lesions, the functional role of T cells and their cytokines in models of psoriasis, the 
therapeutic efficacy of drugs directed at the immune system, the findings that some 
psoriatics get cured on receiving bone marrow transplantation and that psoriatic 
transplant donor can transfer psoriasis to the recipient and that top hits in the whole-
genome scans of genes and mRNA are immune-related (Mahil et al., 2016; Nestle et 
al., 2009). 
The pathogenesis is now believed to involve dysregulated innate and adaptive 
immune responses in the skin to unknown antigens in a genetically susceptible 
individual; replacing the older concept of being a pure keratinocyte proliferation 
disorder with the occurrence of T cell activation and skin infiltration as a secondary 
event. Currently, both psoriasis and psoriatic arthritis are looked at as autoimmune 
disorders (Brotas et al., 2012; Coimbra et al., 2012; Girolomoni et al., 2012; Lee et 
al., 2012; Mitra et al., 2013).  
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Skin has been viewed as the second large innate immune organ in human body 
providing both a physical barrier and an immune-surveillance system (Møller-
Kristensen et al., 2007). This surveillance system is composed of APCs, 
epidermotropic T cells, cytokine-secreting keratinocytes, dermal capillary endothelial 
cells, mast cells, tissue macrophages, fibroblasts, granulocytes, lymph nodes, and non-
Langerhans cells. All these cells communicate together by cytokine production and 
accordingly respond upon stimulation by chemicals, ultraviolet light, bacteria, and 
other irritating factors (Coimbra et al., 2012).  
In psoriasis, there is interaction between the innate and adaptive immune systems 
cells and resident cells in the skin, including keratinocytes, fibroblasts, mast cells and 
endothelial cells (Girolomoni et al., 2012, Mitra et al., 2013). 
In brief, antigen presenting cells - immature dendritic cells of the skin – on  
exposure to a still unknown antigen are activated, migrate to lymph nodes, present 
this antigen to T cells starting their activation and differentiation (Coimbra et al., 
2012; Lee et al., 2012). Interestingly dendritic cells in psoriasis lesions are eight 
times more capable of activating T cells than those of uninvolved or normal skin 
(Nestle et al., 1994). However, the event causing the initial activation of dendritic 
cells has not been fully recognized yet (Coimbra et al., 2012; Lee et al., 2012).  
Innate and adaptive immune response in psoriasis involves activation of three 
inflammatory pathways; IL-12/Th1, IL-23/Th17 and IL-22/Th22 (Mitra et al., 2013). 
a- Antigens: 
The primary event in psoriasis development is the uptake and presentation of - still 
unknown - antigen by antigen presenting cells (APCs). Such hypothetical antigen may 
be an exogenous antigen; streptococcal antigen is the most accused one as the 
exacerbation of psoriasis or induction of the disease usually follows streptococcal 
pharyngitis or tonsillitis this typically occurs in guttate psoriasis (Sticherling, 2005).  
Some evidences indicate the presence of self-antigens, although their nature is still 
unknown.  Psoriasis is believed to result from self-continued activation of auto-
reactive T cells due to exposure to keratinocyte-derived autoantigens (Albanesi et al., 
2010). 
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b- Antimicrobial peptides and proteins (AMPs): 
They are short (＜100 amino acids) positively charged molecules. They bind to 
and interact with the negatively charged membranes of microorganisms and kill. The 
exact mechanisms of killing are still not fully understood. AMPs may form pores in 
the membrane of microorganisms leading to lysis of the pathogenic threat (Büchau 
and Gallo, 2007). Antimicrobial peptides are upregulated in the skin during infection, 
inflammation and injury. They are expressed by keratinocytes, cells of eccrine gland, 
mast cells, and infiltrating immune cells (e.g. de-granulated neutrophils, natural killer 
cells) (Büchau and Gallo, 2007; Reinholz, et al., 2012). 
Recent studies showed that AMPs not only function as simple antibiotics but also 
function as chemokines, proteinase inhibitors, and neuropeptides. Moreover, AMPs 
are involved in wound healing, induction of pro-inflammatory cytokine response, 
vascularization and skin differentiation processes. AMPs expression in epidermal 
keratinocytes is induced by high Ca+2 concentration, retinoid acid, and 1,25 (OH)-
vitamin D3 (Büchau and Gallo, 2007; Reinholz, et al., 2012). Due to these versatile 
functions of AMPs as activators of adaptive immunity and inflammation the are called 
‘‘alarmins’’ (Peric et al., 2009). 
Many evidences link AMPs with psoriasis pathogenesis. 1st AMPs are highly 
expressed in psoriasis lesions. 2nd the Koebner phenomenon, development of a 
psoriatic plaque after trauma of unaffected skin, could be attributed in part to the 
AMPs. On skin injury AMPs are upregulated and could be the trigger for the 
development of a psoriatic plaques in a genetic predisposed subject (Büchau and 
Gallo, 2007).  
Many AMPs have been studied in psoriasis: 
1. Human β-defensins (HβDs): 
Human β-defensins (hβDs) are secreted by neutrophils among other cells e.g. 
epithelial cells. hβD-1 is constitutively expressed in epithelia while hβD-2 and hβD-3 
are highly upregulated in inflamed skin including psoriasis. hβD- 1, 2 & 3 have 
antimicrobial activity. hβD-2 and hβD-3 are expressed in psoriatic skin under the 
influence of TNF-α, interferon- γ (INF-γ), IL-1, IL 22 via STAT 3 activation  and by 
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IL-17A through JAK and (Nuclear Factor κ B) NF-κB (Büchau and Gallo, 2007; 
Nomura et al., 2003; Peric et al., 2009).  
2. Human Cathelicidins (LL37): 
Cathelicidin is secreted by epithelial cells and neutrophils. In human healthy skin it 
is present in very low levels however upon injury or infection its production is 
induced in these cells. Vitamin D is a potent inducer of LL-37 in cultured human 
keratinocytes (Büchau and Gallo, 2007; Peric et al., 2009; Reinholz et al., 2012). 
Cathelicidin (LL-37) has wide antimicrobial activity against bacteria, viruses and 
fungi. Along with this antimicrobial function, LL-37 enhances cytokine and 
chemokine secretion from local cells e.g. keratinocytes, and mast cells. Furthermore, 
it influences angiogenesis, increases the proliferation of endothelial cells and 
suppresses induction of apoptosis in keratinocytes (Peric et al., 2009; Reinholz et al., 
2012). 
In psoriatic plaques, there is increased level of LL-37 expression (Büchau and 
Gallo, 2007). It is believed that it plays a role in starting the auto inflammatory 
cascade of psoriasis as LL-37 forms complexes with self DNA activating dermal 
plasmacytoid dendritic cells (pDCs) through its TLR 9. So LL-37 transforms the inert 
self-DNA into a potent trigger of interferon liberation by pDCs in psoriatic lesion; 
pro-inflammatory (Reinholz et al., 2012). 
3. S100 proteins: 
S100 proteins are of low molecular weight (9–13 kDa). Fourteen of the 21 S100 
genes are present in the epidermal differentiation complex on chromosome 1. Thirteen 
S100 proteins are synthesized in normal and/or diseased epidermis. Specific S100 
proteins are upregulated in psoriasis, during wound healing, inflammation, cellular 
stress, arthritis, skin cancer and metastasis (Büchau and Gallo, 2007). 
S100A7, S100A8 (calgranulin A), S100A9 (calgranulin B), S100A12 (calgranulin 
C) and S100A15 have a putative innate immune role (Büchau and Gallo, 2007). 
Along with the antimicrobial activities, multiple S100 proteins are involved in the 
control of epidermal maturation and are highly upregulated in psoriatic plaques. 
S100A7 & S100A15 have been shown to be strongly overexpressed in keratinocytes 
 	  
	   Review of Literature 	  
	   	  
13 	  
on stimulation with high Ca+2 and pro-inflammatory cytokines (Büchau and Gallo, 
2007). 
c- Dendritic cells: 
Dendritic cells (DCs) are the key sentinels of the immune system which bridge the 
gap between the innate and the adaptive immune systems. Dendritic cells are not only 
antigen-presenting cells but activate T cells present in the dermis and epidermis, as 
well (Coimbra et al., 2012; Nestle et al., 2009). Dendritic cell subtypes include 
myeloid (mDCs) and plasmacytoid (pDCs)(Ueno et al., 2011). 
It is interesting to know that DCs outnumber T cells in psoriatic lesions. This 
highlights their role in psoriasis pathogenesis. pDCs represent 16% of the dermal 
infiltrate in lesional psoriatic skin, on the contrary they don’t exist in normal skin 
(Hari et al., 2010; Zaba et al., 2009). 
Of myeloid DCs (mDcs), only Langerhans cells (LCs) are seen in the epidermis, 
while two DC subsets CD1a+ DCs and CD14+ DCs are found in the dermis (Ueno et al., 
2011). Langerhans cells (LCs) are the DCs of the epidermis and other stratified 
squamous epithelia. They express a Langerin ⁄CD207 marker. (Steinman & Idoyaga 
et al., 2010)  
Langerhans cells express TLR 1, 2, 3, 6, and 10. They produce only few cytokines, 
including IL-15, a cytokine known to enhance CD8+ T cell responses. (Ueno et al., 
2011)  
In 2005 Nestle and coworkers identified pDCs and its cytokine IFN-α as an 
important upstream initiators for psoriasis development. Moreover, they proposed that 
targeted therapy against pDCs and their IFN-α should be taken in consideration for 
the prevention and early intervention in psoriasis (Nestle et al., 2005). One of pDCs 
activators is stressed keratinocytes which under environmental triggers as infections 
release self-DNA and self-RNA complexed with the cathelicidin (LL-37). Both 
complexes (self-DNA-LL37 & self-RNA-LL37) activate pDCs to secrete IFN-α 
initiating psoriatic lesions (Denadai, 2013; Lande et al., 2007; Prignano et al., 
2012). High amounts of IFN-α produced by activated pDCs induce a strong activation 
of the local immune system; mainly myeloid dendritic cells - secreting TNF-α, IL12 
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and IL23- and potentially autoreactive T cells which secrete cytokines to further 
promote the pathogenic inflammatory cascade (Denadai, 2013; Nestle et al., 2009).  
Sun exposure rapidly reduces pDCs in psoriatic lesional dermis preceding clinical 
response which suggests that sun induced clinical improvement can be partly 
attributed to its effect on pDCs and their products (Denadai, 2013).  
Farkas and Kemény proposed a new model for psoriasis pathogenesis involved not 
only pDCs and mDCs but also what is known as monocyte derived dendritic cells 
(moDCs) (Figure 4). These moDCs have the combined phenotype of pDCs and 
mDCs along with the characteristics of natural killer (NK) cells and Toll-like 
receptors (TLRs) (Farkas and Kemény, 2012). They are derived from blood 
monocytes which migrate into skin and differentiate into moDCs under the combined 
effect of pDCs’s INF-α and Granulocyte monocyte colony stimulating factor (GM-
CSF) produced by lymphocytes, fibroblasts, mast cells, neutrophils, macrophages and 
keratinocytes. Other cytokines e.g. IL-1β, TNF-α, IL-6 and IFN-γ have an important 
role in tuning phenotypes and functional properties of IFN-α-primed moDCs as 
monocytes may also receive differentiation signals from other cell types such as 
lymphocytes NK cells, NK T cells, macrophages, fibroblasts and keratinocytes 
(Farkas and Kemény, 2012).  
A very interesting fact is that mannose binding lectin (MBL) inhibits 
lipopolysaccharide (LPS) induced maturation of immature moDCs and subsequently 
cytokine production or T cell activation & proliferation (Wang et al., 2011 b). 
d- Monocytes and macrophages: 
The important role of monocytes /macrophages in psoriasis is not clearly defined 
(Lee et al., 2012). The TNFα, IL6, IL1 produced from peripheral blood monocytes of 
active psoriatic patients is higher than produced from same cells of inactive psoriatics 
or healthy controls. This infers that peripheral blood monocytes may be the major 
source of elevated TNFα in psoriasis (Mizutani et al., 1997; Turan et al., 2014). 
Furthermore, monocytes are the source of moDCs recruited & differentiated in the 
skin under the effect of INF-α and GM-CSF (Farkas and Kemény, 2012). 
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Figure 4: Farkas and Kemény psoriasis pathogenesis model. In this model the role of IFN-α-
primed moDCs, TLR stimulation and T lymphocytes is highlighted. 
moDC, monocyte-derived dendritic cell; IFN, interferon; GM-CSF, granulocyte/macrophage 
colony-stimulating factor; IL, interleukin; NK, natural killer; LL37, cathelicidin antimicrobial 
peptide; pDC, plasmacytoid dendritic cell; Th, T-helper; ssRNA, single-stranded RNA; TNF, 
tumour necrosis factor. Adopted from Farkas and Kemény, 2012  
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e- T cells 
Psoriasis is a disease of dysregulated immune system with Th1/Th17 cells 
predominance (Figure 5). Many observations support such belief; an increase in Th1 
cytokine profile (IFN γ, TNF α, IL 12, and IL 2) is observed in psoriasis plaques 
along with patient’s serum, inferring a systemic release of cytokines towards Th1 
dominance. Moreover, the circulating levels of IFN γ, TNF α and IL 12 correlates 
significantly with disease severity and the clinical success of classical therapeutics is 
associated with the deviation from a Th1 to a Th2 profile  (Coimbra et al., 2012; Lee 
& Hwang, 2012). Interestingly, psoriatic lesions cured on the accidental receiving of 
psoriatic patients a hematopoietic stem cell transplant from a non-psoriatic donor. On 
the contrary, psoriasis frequently develops in recipients of bone marrow transplants 
from a psoriatic donor, the recipient also frequently develops psoriasis (Sabat et al., 
2007). The major evidence of the key role of Th1/Th17 cells and their cytokine in 
psoriasis is the success of biologic therapy of psoriasis (Brotas et al., 2012; Coimbra 
et al., 2012; Sabat et al., 2007).  
 
 
 
 
 
 
 
 
In psoriasis, on antigen presentation, T lymphocytes enter the circulatory system 
and, through cell-cell interactions with the endothelial cell lining of blood vessels 
(Figure 6), they migrate to inflamed skin and accumulate around the dermal blood 
vessels (Coimbra et al., 2012; Jiaravuthisan et al., 2007). 
 
Figure 5: T cell differentiation in psoriasis.  
Naïve T cell differentiates to various T cells depending on the stimulus. Naïve T 
cells differentiate to Th1 & Th17 in psoriasis. INFγ, IL17A, IL17B, IL 21 & 
IL22 all enhance keratinocyte proliferation. mDC, monocyte derived dendritic 
cells  Adopted from Mahil et al., 2016  
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The naïve T helper cells differentiate into effector cells such T helper 17 cells 
(Th17) and T helper 1 cells (Th1) (Nestle et al., 2009) (Figure 5). 
T helper cells differentiate into Th1 under the influence of IFN-γ which increases 
IL-12 specific receptor chain expression. IL12 drives Th1 cell-mediated immune 
response development and locally IL12 plays a role in induction of new psoriatic 
lesions (Coimbra et al., 2012; Lee et al., 2012). Th1 cytokine profile includes TNF-α 
and INF-γ.  
The differentiation of naïve T helper cells into Th17 happens under the influence 
of IL6, IL1 and TGF β.	   They induce the activated memory Th17 cells differentiation 
from naive CD4+ T cells and stimulate the expression of IL17A and IL23 receptors. IL-
23 drives Th17 cell proliferation and enhances more IL17A production along with 
other cytokines e.g. IL 17F, IL 21and IL 22 (Coimbra et al., 2012; Girolomoni et 
al., 2012; Nestle et al., 2009).  
Figure 6: Immunopathogenesis of psoriasis.  
The antigen (Ag) is recognized and engulfed by APCs which   migrate to lymph 
node where T cell differentiation occurs. Differentiated T cells get back to skin. 
On blood vessel wall VCAM, ICAM and E& P selectins of endothelial cells 
binds to VLA4, LFA1 and CLA on T lymphocytes. Ag, Antigen; APCs, Antigen 
presenting cells; ICAM, Intercellular Adhesion Molecule; VCAM, Vascular cell 
adhesion protein; VLA-4, Very Late Antigen-4; LFA-1, Lymphocyte function-
associated antigen 1; CLA, Cutaneous Lymphocyte Antigen.  Adopted from 
Jiaravuthisan et al., 2007 
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The orphan nuclear receptor (Retinoic acid related Orphan Receptor) RORγt is the 
first specific transcription factor expressed in Th17 cells. IL 6 in combination with 
TGF-β, amplify this Th17 cell RORγt-dependent differentiation (Ivanov et al., 2006; 
Coimbra et al., 2012). Moreover, IL 6 induces IL 21 expression with more induction 
of IL 21 & IL 23 receptors in naive CD4 (+) T cells (Coimbra et al., 2012). IL 6 and IL 
21, via signal transducer and activator of transcription 3 (STAT3), promote Th17 cell 
differentiation. STAT3 also promotes RORγt expression. IL 21 and IL 23 induce 
RORγt, which, in synergy with STAT3, promote IL 17 expression (Mathur et al., 
2007; Coimbra et al., 2012).  
T helper 17 cytokine profile includes IL 17, IL 22 and IL 21. 
γδ T cells function as innate-like cells; involved in immune surveillance of the skin  
with immediate response capabilities and they amplify Th17 cell immune response 
upon their activation by IL 23, IL 1β or danger signal stimulation (Cai et al., 2013; 
Laggner et al., 2011).  
γδ T cell role in psoriasis development has been illustrated both in animal models 
and human. In T cell receptor δ deficient (TCRδ −/−) mice, the epidermal acanthosis, 
inflammation and IL-17 levels were significantly lowered. In humans, γδ T cells are 
detected at high frequency in psoriatic lesions and are capable of producing large 
amounts of IL-17 in response to IL-23 stimulation (Cai et al., 2013). Skin-homing 
Vγ9Vδ2 T cell subset is the subset of γδ T cells detected in psoriatic skin, the exact 
source of which yet to be identified. Some studies claims that they are redistributed 
from blood to psoriatic skin based on their low peripheral blood level in psoriatics 
compared to healthy control. This level gets normalized with successful therapy using 
psoriasis-targeted therapeutic (Cai et al., 2013; Laggner et al., 2011). Other suggests 
local expansion in the skin under inflammatory condition (Cai et al., 2013).  
The cytokine profile of γδ T cells includes	  TNF-α, IFN-γ and IL-17A, along with 
pro-inflammatory chemokines such as IL-8, CCL4, CCL3, and CCL5. They are 
important for the recruitment of key immune effector cells to the skin (Cai et al., 
2013; Laggner et al., 2011). 
Many studies addressed the role of newly discovered T cell subset; Th 22 in the 
pathogenesis of psoriasis. Kagami and coworkers proved increased circulating Th 22 
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cells in psoriatic patients among other T cells subsets (Kagami et al., 2010). Nograles 
and coworkers showed that the main source of IL22 secretion in psoriatic plaques is 
Th 22 and Th 17 (Nograles et al., 2009). The role of Th 22 in psoriasis pathogenesis 
is conducted through its IL22 production discussed in detail later on. 
Despite the evident and major role of T cells in the pathogenesis of psoriasis, the 
cause of this sustained T cell response is need to be identified and whether it is due to 
recognition of autoantigens in psoriatic plaque or due to proliferation of memory T 
cells on exposure to cytokines in an antigen – independent way (Girolomoni et al., 
2012). 
f- Cytokines: 
Cytokines are small (8-80 kD), biologically active proteins. They regulate cell 
growth, differentiation and function. They also aid in steering the immune response 
and inflammation.	   On cellular activation, they get released in brief, self-limited 
events. The actions of cytokines are usually redundant and pleiotropic meaning they 
are able to act on different cell types (Brotas et al., 2012; Coimbra et al., 2012). 
Cytokines are divided into groups based on their biological actions; mediators of 
innate immunity, mediators of adaptive immunity, and stimulators of hematopoiesis. 
They are also classified based on the structural similarities in between and the 
similarities in their receptors sequence. Regardless of the classification, different 
cytokines share receptor subunits, hence network and functional redundancy (Brotas 
et al., 2012). 
The psoriatic lesion results from interactions between many different cell types. 
Such strong interdependence between these cells is only available through a complex 
network of growth factors, various chemokines and pro-inflammatory cytokines 
(Figure 7), such as interleukins, IFN γ, and TNF α (Brotas et al., 2012; Coimbra et 
al., 2012).	   
Psoriasis is accepted as a Th1/Th17 inflammatory disease, hence is associated with 
an increase in Th1 and Th17 cytokines (Coimbra et al., 2012). Different cytokines 
involved in the pathogenesis of psoriasis (Figure 7) (Brotas et al., 2012). 
1. Type I Interferons: 
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Type I IFNs include IFN α, β, ω, δ, τ, κ subtypes. IFN α is the dominant type I IFN 
in psoriatic skin (Yao et al., 2008; Zheng et al., 2007; Baliwag et al., 2015).  
Plasmacytoid dendritic cells (pDCs) are the major professional INF α secreting 
cells in the body (Denadai, 2013; Farkas and Kemény, 2012; Prignano et al., 
2012; Zheng et al., 2007). 
 
 
2. Interferon- γ: 
IFN-γ is a type II IFN, mainly secreted by activated Th1 cells, dendritic cells, and 
NK cells (Coimbra et al., 2012; Yao et al., 2008). Early in psoriasis and under the 
influence of IFN-α naïve T cells differentiate into Th1 cells producing IFN-γ and 
TNF-α. The secretion of IFN-γ is under the influence of IL2 from T cells, IL12 from 
Langerhans cells and IL18 which synergizes the action of IL12 (Fantuzzi et al., 
1999; Coimbra et al., 2012). IFN-γ induces several chemokines in keratinocytes 
including CCL2, CXCL2, CXCL9, CXCL10 and CXCL11 which increase the 
chemotaxis of immune cells. IFN-γ activates monocytes/macrophages, dendritic cells, 
and endothelial cells. IFN-γ inhibits keratinocytes apoptosis, so in part it contributes 
to keratinocyte hyperproliferative state observed in psoriatic lesions, and it also 
stimulates epidermal cell proliferation (Coimbra et al., 2012; Sabat et al., 2007). 
3. Tumor Necrosis Factor-α: 
Figure 7: Cytokines of psoriasis. Various cytokines, and their role in Psoriasis 
development. The main cytokines are grouped based on the processes they affect. 
Pleiotropism, redundancy and induction of these cytokines are evident. Modified 
from Brotas et al., 2012. 
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Tumor necrosis factor α (TNF- α) is a key player in psoriasis development. Its 
expression level is increased both locally in lesional skin and systemically in the 
serum of the patients (Brotas et al., 2012). Macrophages & monocytes are the main 
source of TNF α, yet it get secreted by a various immune and non-immune cells as 
well including neutrophils, dendritic cells, natural killer cells, endothelial cells, 
keratinocytes, melanocytes and fibroblasts (Coimbra et al., 2012).  
    In psoriasis, TNF-α affects different cells, and increases the ICAM 1 expression on 
dermal endothelial cells with subsequent enhanced infiltration of T cells and 
monocytes into skin (Figure 6) (Brotas et al., 2012; Jiaravuthisan et al., 2007). 
TNF-α upregulates IL-6 expression which in turn drives Th17 differentiation. IL 6 
also stimulates keratinocyte proliferation (Brotas et al., 2012; Coimbra et al., 2012). 
IL-8, a chemotactic cytokine, is induced by TNF-α. TNF-α increases, the keratinocyte 
proliferation marker, Cytokeratin 6 (CK6) expression which stimulates keratinocyte 
hyperplasia (Brotas et al., 2012; Coimbra et al., 2012; Lee et al., 2012). TNF α 
enhances the NF-κB inhibitory protein, I-κB, degradation. NF-κB is a transcription 
factor of TNF-α, IL-6, IL-8, E-selectin, VCAM1 and ICAM1. TNFα also enhances 
receptors of vasoactive intestinal peptide (VIP) resulting in keratinocyte proliferation. 
(Coimbra et al., 2012; Lee et al., 2012; Brotas et al., 2012) Induction of Vascular 
Endothelial derived growth factor (VEDGF) by TNF-α enhances angiogenesis. TNF-α 
is the facilitator of LCs migration from epidermis initiating the immune response 
(Figure 7). This happens through inhibition of epidermal intercellular adhesion 
molecules, E-cadherins, (Brotas et al., 2012).  
g- Interleukins: 
Interleukins are cytokines produced by leukocytes and act on them (Brotas et al., 
2012)  
1. Interleukin 1(IL-1): 
IL-1 is called a primary cytokine as it independently initiates a number of 
mechanisms capable of triggering inflammation. (Brotas et al., 2012)  
In psoriasis, IL-1 increases adhesion molecules expression, stimulates 
angiogenesis, activate T cells, induce IFN-γ, TNF-α, IL-8, IL-6 and GM-CSF 
synthesis and it promotes keratinocyte proliferation. Koebner phenomenon can be 
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attributed to IL-1 release, when skin is subjected to trauma, keratinocyte release 
cytokines locally, leading to the development of new psoriatic lesions in some 
patients. IL-1 regulates almost 400 genes associated with cell adhesion, proteolysis, 
signal transduction, and abnormal epidermal differentiation processes observed in 
psoriasis (Figure 7) (Brotas et al., 2012; Yano et al., 2008). 
2. Interleukin 2: 
IL-2 (Figure 7) is a growth factor for lymphocytes and is increased in psoriatic 
plaques. Its receptors are expressed in activated T lymphocytes and their level in 
patients’ plasma coincides with the severity of the disease and response to therapy 
(Brotas et al., 2012). 
3. Interleukin 6: 
Typically IL-6 acts as a regulator of the expression of other cytokines. It is 
involved in cellular proliferation and differentiation. It induces acute-phase proteins in 
the inflammatory reaction. IL-6 (Figure 7) is detected in normal human skin in basal 
keratinocytes, fibroblasts endothelial cells and mononuclear cells (Brotas et al., 
2012). In psoriasis it is expressed the most in the superficial vascular plexus and at the 
top of dermal papillae (Brotas et al., 2012). 
IL-6 is an autocrine mitogen; induce mitosis in cells producing it. In psoriatic 
epidermis, IL-6, in synergy with IL-1 and TNF-α, contribute to keratinocyte 
hyperproliferation via its action on the epidermal growth factor receptor (EGF) 
(Mitra et al., 2013; Brotas et al., 2012). 
Moreover, IL-6, secreted by DCs, with IL1β and TGF-β induce Th17 response. IL-
6 blocks regulatory T cell response as well (Mahil et al., 2016; Kupetsky et al., 
2013).  
The efficacy of etanercept, a fusion protein binds to TNF-α, in psoriasis treatment 
has been associated with reduction of IL-6 level even more than the reduction 
observed in TNF-α. 
Elevated IL-6 level has been found to coincide with arthritis, diabetes and obesity 
in psoriasis, which highlights the role of IL-6 in the systemic inflammatory nature of 
the disease. The relationship between increased IL-6 level and obesity and diabetes 
can be explained in part by the observation of decreased insulin effect on adipocytes 
and hepatocytes after exposure to IL-6 which matches with the finding of increased 
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IL-6 level to 2 – 3 times the control in plasma of diabetics and obese (Brotas et al., 
2012).    
4. Interleukin 8: 
IL-8 (CXCL8) (Figure 7) is a chemokine typically responsible for neutrophil 
chemotaxis, promotes keratinocyte proliferation and stimulates angiogenesis. Its level 
is increased in psoriasis both in psoriatic plaques and serum of the patients. IL-8 
mobilizes as well as activates T lymphocytes, basophils and natural killer cells in 
psoriasis. IL-8 is a common ligand for both CXCR1 and CXCR2 (Brotas et al., 2012; 
Coimbra et al., 2012; Lee and Hwang, 2012). 
5. Interleukin 12: 
IL-12 is the key cytokine driving of Th1 development.	  IL-12 is formed of two 
subunits (p40 & p35) linked by disulfide bond (Coimbra et al., 2012; Zheng et al., 
2007). Activated macrophages and DCs are the major source of IL-12 upon microbial 
stimulation (Coimbra et al., 2012; Zheng et al., 2007). 
IL-12 activates STAT 4 which in turn increases IFN-γ expression. IFN-γ 
through STAT 1 activation enhances T-bet (T -box expressed in T cells) signaling 
leading to further increase in IFN-γ production and down regulation of Th 2 
cytokines. IL-12's main function is fighting bacterial and intracellular parasites 
(Mitra et al., 2013). 
6. Interleukin 23: 
A heterodimer consist of a p19 subunit and a shared p40 subunit with IL-12. IL-23 
is produced by dendritic cells and by macrophages (Coimbra et al., 2012;	  Mitra et 
al., 2013; Zheng et al., 2007). IL 23 receptor chains are expressed on T cells and NK 
cells (Zheng et al., 2007). According to Coimbra and coworkers IL-23 is a key 
master cytokine regulator in psoriasis pathogenesis (Coimbra et al., 2012).  
  The role of IL 23 in psoriasis is evident in genetic association studies identifying 
a SNP in the 3'-UTR of the IL12B gene and two SNPs in the IL23R gene to be 
associated with psoriasis. In culture, keratinocytes extracted either from normal or 
lesional psoriatic skin express constitutively subunits of IL 23. The mRNA of p40 & 
p19 IL 23 subunits are upregulated in psoriatic plaques. Furthermore, improved 
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psoriatic lesions which received narrow-band ultraviolet-B (NB-UVB) phototherapy 
was found to be associated with reduction in IL-23 expression in lesional skin. 
Moreover, there is the proven efficacy of Ustekinumab, a monoclonal antibody 
against the shared p40 subunit of IL 23 and IL12, in psoriasis therapy (Coimbra et 
al., 2012; Mitra et al., 2013; Zheng et al., 2007). 
The role of IL-23 in psoriasis includes Th 17 cells activation, survival, 
proliferation and terminal differentiation (Coimbra et al., 2012; Mitra et al., 2013). 
Furthermore it induces keratinocyte hyperplasia via its downstream mediators IL-22 
and IL-17 as proved by Rizzo and coworkers. They proved that both IL-17 and IL-22 
are essential for IL-23 mediated epidermal hyperplasia and any one of them alone is 
not sufficient to produce the IL-23 effect (Rizzo et al., 2011). IL-23 also induces 
mixed inflammatory cells to infiltrate the dermis and it enhances TNF-α production 
by macrophages (Coimbra et al., 2012).  
7. Interleukin 17: 
IL-17 family is composed of 6 isoforms (IL17A - IL17F) of those 6 IL17A and 
IL17F are the main isoforms expressed by T lymphocytes in psoriasis. IL 17A & F 
have the ability to work as monomers; each one binds alone to the receptor or work as 
a heterodimer with each other IL-17A/F (Ariza et al., 2012; Girolomoni et al., 2012; 
Kupetsky et al., 2013). IL 17A is about 20 times stronger than IL-17F in activating 
downstream genes whereas the IL-17A/IL-17F heterodimer have intermediate 
activity. IL-17 exerts its biological action through binding to family of receptors IL-
17R (A-E) (Girolomoni et al., 2012). 
IL-17 is produced by Th17 cells, Tc17 cells, γδ T cells, neutrophils and mast cells. 
It is interesting to know that mast cells and neutrophils are present in higher densities 
than Th17 cells in psoriatic plaques (Ariza et al., 2012; Girolomoni et al., 2012).  
IL-17 works with IL-22 to initiate immune response against extracellular invaders 
by inducing antimicrobial peptides and chemokines expression resulting in neutrophil 
recruitment. IL-17 has a role in tissue inflammatory response on the other hand IL-22 
is responsible for tissue regeneration (Girolomoni et al., 2012). 
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Evidences supporting the role of IL-17 in psoriasis development include increased 
blood level of IL-17 in psoriatic patients correlated with disease severity. IL-17 
mRNA was detected in psoriatic plaques. Furthermore, in experimental models 
blocking of IL-17A improved psoriasis-like pathology along with the fact that the 
response to anti TNF-α therapy is associated with reduction in IL-17 signaling and 
down regulation of IL-17 regulated genes among responders only (Coimbra et al., 
2012; Girolomoni et al., 2012).  
IL-17 (Figure 8) produces and maintains psoriatic plaques through different 
mechanisms (Girolomoni et al., 2012). IL-17 recruits different types of cells to the 
psoriatic lesions through induction of keratinocyte chemokine (CCL20) expression. it 
binds the chemokine receptor (CCR6). Thus CCR6+ cells like Th-17 and mDCs is 
being recruited to psoriatic plaques creating positive feedback loop and maintaining 
the presence of both cells in psoriatic lesions. Worth mentioning responders to anti 
TNF-α therapy show downregulation of CCL20. Furthermore, IL-17A stimulates the 
expression of CXCL1, CXCL3, CXCL5, CXCL6 and CXCL8 chemokines activating 
CCR1 and CXCL2. The latter further activates CCR2. Both CCR1 and CCR2 are 
involved in neutrophil attraction to form subcorneal micro-abscesses in psoriatic 
epidermis (Girolomoni et al., 2012).  
Moreover, IL-17A increases IL-6 secretion by fibroblasts and mDCs which, in 
turn, drives more T cells to the Th17 phenotype (auto reactive loop). IL-17A also 
stimulates production of TNF-α and IL-1 by mDCs and macrophages (Coimbra et 
al., 2012; Girolomoni et al., 2012). 
Another role of IL-17A in psoriasis development is achieved via induction of 
antimicrobial peptides expression as β-defensin 2, S100A7, S100A8 and S100A9 
which act as stimulus for innate immune response (Coimbra et al., 2012; 
Girolomoni et al., 2012).  
Recently psoriasis has been considered as a systemic condition with higher rate of 
developing cardiovascular accident, diabetes and obesity. IL-17A, presents at higher 
concentrations in the blood of psoriatic patients compared to normal control, has been 
linked to atherogenesis (Girolomoni et al., 2012).  
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8. Interleukin 22 
Different cells produce IL-22 includes Th22, Th17, Th1, DCs and macrophages 
(Coimbra et al., 2012; Fujita, 2013). 
In the skin IL-22 targets the keratinocytes for amplification as well as maintenance 
of inflammation (Coimbra et al., 2012). IL-22 mediates the crosstalk between 
epidermal cells and leukocytes rather than regulating immune cells. Furthermore, IL-
22 acts with IL17 in regulating the antimicrobial peptide production including the 
induction of S100A7, S100A8, S100A9, β-defensin-2, and β-defensin-3 gene 
expression. IL-22 also induces epidermal hyperplasia (acanthosis), and inhibits 
keratinocyte terminal differentiation (hypogranulosis). Moreover, induces pro-
inflammatory responses, such as the production of multiple cytokines, various 
chemokines, and acute-phase proteins from different cell types (Baliwag et al., 2015; 
Coimbra et al., 2012; Fujita, 2013; Tohyama et al., 2012). To sum up IL-22 works 
on keratinocytes rather than immune cells regulating three functions: (i) production of 
antimicrobial peptides, (ii) keratinocyte differentiation and (iii) keratinocyte migration 
(Sabat et al., 2007). 
Figure 8: Roles of interleukin (IL)-17A in psoriasis. IL-17A stimulates the production of 
pro-inflammatory chemokines and cytokines, These mediators promote infiltration of 
multiple cell types to psoriatic lesions, including myeloid dendritic cells (mDCs), Th17 cells 
and neutrophils. Dotted lines indicate that some of these actions may act as a positive 
feedback loop which sustains the chronic inflammatory response in the skin. DCs, dendritic 
cells; TNF, tumor necrosis factor Adopted from Girolomoni et al., 2012 
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 IL-22 is one of the most important cytokines in the pathogenesis of psoriasis 
(Tohyama et al., 2012). This is evident via many facts; the up-regulated IL-22 
expression in psoriatic lesions clearly decreases after anti-psoriatic therapy. Even 
more, IL22R expression is enhanced in psoriatic skin compared to normal skin. Serum 
IL-22 levels are also higher in psoriasis patients than in healthy controls, and these 
levels significantly correlate with disease severity. Furthermore, the significant 
reduction of serum IL-22 after treatment is achieved (Coimbra et al., 2012; Fujita, 
2013). 
The production of IL-22 is influenced by IL-6 and IL-23 in vitro. However, in vivo 
IL-6 seems to have no role. It seems that the IL-23 induced keratinocyte hyperplasia 
is mediated through IL-22. It was proved that IL-22 blockade abolished significantly 
the IL-23 induced keratinocyte hyperplasia (Ariza et al., 2012; Coimbra et al., 
2012).  Furthermore, Tohyama and coworkers proved that IFN-α enhances the effect 
of IL 22 on keratinocytes via increasing IL-22 Receptor expression (Tohyama et al., 
2013). 
9. Interleukin 19,interleukin 20, interleukin 24: 
They are of IL-10 family. Activated monocytes secrets both IL-19 and IL-20 while 
IL-24 is secreted by Th2 cells, monocytes and melanocytes (Zheng et al., 2007). 
Their receptors are expressed mainly on epithelial cells and signals through STAT3 
promoting tissue remodeling, wound healing, and antimicrobial peptide expression 
(Baliwag et al., 2015). TNF-α and IL1β induce the production of IL-19 and IL-20 
from myeloid cells. As IL22, they promote the crosstalk between keratinocytes and 
activated myeloid cells (Zheng et al., 2007).  
h- Chemokines: 
Chemokines are small cytokines (8-11 kDa in size), small chemotactic substances 
guide the movement of leukocytes towards inflammation sites. (Lee and Hwang, 
2012). As chemo-attractant factors they stimulate directional movement of all types of 
leukocytes through regulated group of chemokine receptors expressed on the surface 
of T cell subsets including Th1, Th2, Th17, Treg, and memory T cells. This enable T 
cells to differentially respond to specific chemokines. Along with this chemotactic 
ability, chemokines enhance the leukocytes’ rolling and adhesion to endothelial cells 
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by enhancing the affinity and avidity of leukocytes’ surface β1 and β2 integrins (Lee 
and Hwang, 2012). 
In the skin, keratinocytes are capable of expression of multiple chemokines that 
attract certain leukocytes, such as T cells or dendritic cells (DCs), toward the 
epidermis (Lee and Hwang, 2012). 
1. CCR 6: 
CCR6 has an important role in the chemotaxis of Th17. CCL20 is the recognized 
CCR6’s ligand, however human β-defensin 2 (hβD2) attracts leukocytes via CCR6 as 
well. In psoriatic patients, peripheral Th17 cells expressing CCR6 are increased both 
in skin and in blood. IL-23 from DCs maintains dermal CCR6+ Th17 cells (Lee and 
Hwang, 2012). 
Langerhans cells also express CCR6 and are attracted to CCL20. CCR6 is 
supposed to have a role in macrophage maturation although it is not expressed on 
fully mature macrophage (Lee and Hwang, 2012).   
2. CCL 20: 
As mentioned before it is an exclusive ligand for CCR6. It is expressed normally 
by keratinocytes and dermal endothelial cells. This expression is increased in pro-
inflammatory conditions as in the presence of TNF-α, IL-17, IL-1α and IFN-γ. In 
psoriasis, CCL20 is excessively expressed in epidermis and endothelial cells. CCL20 
recruits circulating CCR6-expressing cells e.g. Th17 cells, γδT cells - both produce 
Th17 cytokines - and LCs into inflamed epidermis (Lee and Hwang, 2012). 
3. β-defensin 2: 
human β defensin 2 (hβD2) signals through CCR6 also. It is highly expressed in 
the epidermis of psoriatic skin. β defensin gene high copy numbers are associated 
with susceptibility to psoriasis. Increased hβD2 production in psoriasis may act in 
synergy with CCL20 to attract the needed populations of CCR6+ expressing cells, 
including Th17 cells (Lee and Hwang, 2012). 
4. CCR10: 
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In psoriasis, CCR10-expressing T cells accounts for more than 90% of T cell 
population and migrate into epidermis under the effect of keratinocyte derived 
CCL27, the CCR10 ligand whose expression is upregulated by TNF- α (Lee and 
Hwang, 2012). 
5. CXCR3: 
CXCR3 is upregulated on Th 1 cells which migrate from dermis to epidermis 
under the influence of its ligands; CXCL9, CXCL10, and/or CXCL11 derived from 
keratinocytes. It is also involved in trans-endothelial migration of T cells (Lee and 
Hwang, 2012). 
6. CCR5 & CCL5: 
CCL5 (RANTES) is one of the ligands for CCR5. It is highly expressed in 
psoriatic lesions. Calcipotriol, an active vitamin D3 analogue and a therapeutic for 
psoriasis, inhibits CCL5 keratinocyte production. Moreover, epidermal T cells and 
dermal macrophages’ CCR5 expression was higher in lesional compared to non 
lesional skin. CCR5+ T cells move to epidermis through interaction with CCL3 and 
keratinocyte -derived CCL5. (Lee and Hwang, 2012). 
To sum up many chemokines and their receptors are accused in psoriasis 
development and progression. Targeting single chemokine ligand or receptor is 
challenging due to redundancy of the chemokine system. However, in mouse models 
of psoriasis, therapeutics targeting the CCR6 pathway showed efficacy. Furthermore, 
the mice lacking CCR6 resist induction of psoriasiform lesions on IL-23 injection 
(Lee and Hwang, 2012).  
i- Keratinocyte: 
Activated Keratinocytes are involved in two processes during psoriasis 
development 1st involves the hyperplasia and increased cell division with altered 
differentiation 2nd involves secretion of cytokines (Coimbra et al., 2012). 
Keratinocytes hyperplasia and altered differentiation is a hallmark feature of 
psoriasis pathology which occurs under effect of multiple cytokines. IL 19, IL 20, IL 
22, IL 24 and others enhance epidermal hyperplasia and altering its differentiation as 
well as activating keratinocyte for secretion of different mediators (Baliwag et al., 
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2015; Zheng et al., 2007). Early in psoriasis, keratinocyte activation is under the 
effect of Th1 cytokines e.g. IFN-γ and IL22. Later on Th 17 cytokines take the upper 
hand e.g. IL-6, IL-17 and IL-22. Macrophages and dendritic cells maintain such 
activation via secreting TNF-α, IL-6, IL- 18, IL-19 and IL-20. Other mediators 
involved in keratinocyte activation are produced by keratinocyte itself as TGF-α and 
nerve growth factor (NGF) and by dermal stromal cells mediators e.g. keratinocyte 
growth factor (KGF), insulin-like growth factor 1(IGF-1), and fibroblast growth factor 
10 (Coimbra et al., 2012; Sabat et al., 2007). 
Keratinocytes produce various mediators that enhance more immune cell 
migration, induce angiogenesis and activate dermal stromal cells. Of their products, 
IL-6, IL-8, TGF-α, TGF-β, and amphiregulin act as neutrophil attractants and growth 
factors for endothelial cells. Moreover, TGF-α and amphiregulin stimulate 
keratinocytes hyperproliferation and are, along with TGF-β, ligands for IL-1 and 
epidermal growth factor receptor, which are expressed in psoriasis (Coimbra et al., 
2012). 
j- Mannose Binding Lectin: 
Mannose Binding Lectin (MBL) is very important player of innate immune system 
(uniprotkb: P11226). It is a Ca+2 dependent collectins family member (Dommett et 
al., 2006; Takahashi, 2011). Collectins are pattern recognition molecules structurally 
composed of carbohydrate recognition domain and collagen- like structures (Jack et 
al., 2001). 
Innate immune system is responsible for the primary defense against harm to the 
body. First the invading pathogens were thought to be the only targets of innate 
immune system later on other targets have been identified including abnormal self-
epitopes e.g. cells and tissues damaged through apoptosis, trauma, inflammation, 
malignancy or other kinds of tissue injury (Takahashi, 2011).   
Successful innate immune protection	   includes both recognition and effector 
mechanisms. The recognition of injurious agents is the responsibility of Pattern 
recognition molecules. Pathogen associated molecular patterns (PAMPs) are 
conserved structures in a particular class of microorganisms, which are not present 
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within the host. These structures are not easily discarded as they are essential for the 
viability of the microorganism (Bergman, 2011).  
Pattern recognition molecules/receptors recognize and bind to these specific 
patterns (PAMPs) in the harmful agents such as the recognition of lipopolysaccharide 
moiety by TLR4 or the recognition of carbohydrate moiety by MBL. These molecules 
are found as cell membrane proteins on innate cells, or as embedded proteins in the 
extracellular matrices, or as soluble proteins circulating in the blood e.g. MBL 
(Takahashi, 2011).  
MBL was primarily acknowledged as a pattern-recognition molecule able to 
distinguish microbial non-self from self, then it become appreciated that MBL can 
also bind to altered self-molecules like apoptotic and necrotic cells (Downing et al., 
2005; Heitzeneder et al., 2012). 
MBL synthesis and secretion: 
MBL, in human, is synthesized mainly in liver (95%) and the remaining amount is 
synthesized in kidney, thymus, tonsil, small intestine and vagina. It was also detected 
in the lungs of healthy individuals and on the smooth muscle of the airway following 
infection (Jack et al., 2001; Takahashi, 2011). MBL is detected in skin after burn 
and in brain after trauma. Following UVB exposure, MBL is detected in the skin and 
mostly recruited into the damaged sub-epithelial tissue from local capillaries. MBL 
aids in clearing apoptotic keratinocytes (Takahashi, 2011). This wide distribution of 
MBL indicates its role as a surveillance system in innate immune system (Takahashi, 
2011). 
MBL serum level is affected by genetic and non-genetic factors e.g. age, sex, 
hormones and infection. MBL is an acute phase protein whose serum levels may 
increase 2–3 folds in response to infection or other inflammatory stimuli 
(Heitzeneder et al., 2012). 
MBL Chemical Structure  
MBL is formed of subunits of trimers (Figure 9) i.e. each subunit contains 3 
peptide chains (trimer) (Dommett et al., 2006; Takahashi, 2011). The peptide chain 
composed of 21 residues, cysteine rich, N terminus domain for the disulfide binding 
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between chains, followed by glycine rich collagen like domain composed of 19 
repeats of Glycine, X and Y where X and Y may be any amino acid but frequently 
proline and hydroxylproline. These repeats get interrupted at one site forming a hinge, 
then α helical coiled-coil hydrophobic part representing the neck of 34 residue, and 
finally the carbohydrate domain with globular configuration at the C terminus (112 
residue) (Dommett et al., 2006; Takahashi, 2011). Then subunits get oligomerized 
in higher order structures to be functional e.g. tetramers and hexamers. Thus the 
ability of MBL to bind to the carbohydrate moieties on pathogens depends on the 
oligomerization into higher order structure (Dommett et al., 2006; Takahashi, 2011; 
Worthley et al., 2005). The hinge in the collagenous region give MBL protein its 
bouquet shaped orientation (Figure 9) (Dommett et al., 2006).  
The carbohydrate recognition domain binds sugars e.g. mannose, N-acetyl-D-
glucosamine, N-acetyl-mannosamine, fructose and glucose (Worthley et al., 2005). 
These carbohydrates not only present on the surface of many pathogens e.g. bacteria 
and viruses but also abnormal self-tissues, which have endogenous neo-epitopes that 
become exposed on apoptotic cells, cell debris, injured and damaged tissues 
(Takahashi, 2011). MBL also binds phospholipids, nucleic acids and non-
glycosylated proteins (Dommett et al., 2006). 
 
Figure 9: MBL structure. 
a: peptide chain 
b: MBL trimer subunit of 3 peptide chain 
c: bouquet like orientaion of tetramers or more. adopted from Heitzeneder et al., 
2012  
 
a	   b	   C	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MBL Gene 
MBL is encoded in human by mbl 2 gene, (Figure 10) on chromosome10q 21–24 
(Dommett et al., 2006; Turan et al., 2014). mbl 1 is a pseudogene in human, 
however it is functional in rats (Turan et al., 2014). It has 4 exons; exon 1 encodes 
for the cysteine rich N terminal domain, the signal peptide and part of collagenous 
region, exon 2 encodes the rest of the collagenous region, exon 3 for the neck region, 
exon 4 encodes the carbohydrate binding domain (Dommett et al., 2006). 
 
Figure 10: mbl 2 gene. Adopted from Ram et. al., 2010 
Different polymorphisms have been identified of mbl2 gene (Figure 10). Three 
SNPs present in exon 1; at codon 52 (D allel), codon 54(B allel), and codon 57 (C 
allel). A refers to the wild type allel. B allele is the commonest of the exon 1 
polymorphisms. C allele is common in sub Saharan African population (Dommett et 
al., 2006; Heitzeneder et al., 2012).  
Other mbl gene polymorphisms occur at promoter site. They include the 
haplotypes H/L (-619), Y/X (−290 for) and P/Q (−66) (Heitzeneder et al., 2012). The 
exon 1 SNPs B and C are associated with faster degradation of their multimers and 
exist mainly as lower order. Functionally, they have a lower mannose binding 
capacity and do not activate complement. This glycine-rich motif defect is not present 
in the D allele, thus the functional defect is not so obvious. Moreover, the D variant 
only happens in association with the high producing promoter variant H (Heitzeneder 
et al., 2012). 
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In general, MBL B, C and D variants can function as an opsonin, but uniformly 
have a severely reduced capacity of complement activation. The deficient MBL might 
range from100 ng/ml up to 1 µg/ml depending on the measurement approach 
(Dommett et al., 2006; Heitzeneder et al., 2012; Worthley et al., 2005). 
Susceptibility to various conditions have been linked to mbl gene polymorphism 
e.g. brucellosis (Bayram et al., 2012), leprosy (De Messias-Reason et al., 2007) and 
immune diseases as Psoriasis (Turan et al., 2014). 
MBL Functions 
Functional MBL exerts several functions including opsonization, induction of pro-
inflammatory responses early in infection, and lectin dependent complement 
activation (Dommett et al., 2006; Takahashi, 2011).  
1. Complement activation: 
Upon binding the carbohydrate moiety of the pathogen, MBL activates one of the 
MBL-associated serine Proteases (MASPs), which are of four types MASP 1, 2, 3 and 
MAp 19 a truncated MASP2 resulting in complement activation. MBL/MASP 
interaction occurs at the collagen like domain (Jack et al., 2001; Dommett et al., 
2006). MBL- MASP2 complex (Figure 11) cleaves C4 & C2 forming C4bC2a which 
is a C3 convertase (Dommett et al., 2006). MBL–MASP1 complexes also can 
activate C3 directly (Dommett et al., 2006; Flyvbjerg, 2010). 
 
 
 
 
 
 
 
 
Figure 11: Complement activation pathways. Antibodies bind to C1 complex activates classical 
pathway. The Lectin pathway is activated via MBL’s recognition of carbohydrates Spontaneous C3 
activation starts the alternative pathway.  All pathways meets at C3 cleavage with anaphylatoxin 
secretion & inflammatory cells recruitment, opsonization, and the membrane attack complex formation 
with pathogen lysis. MBL, mannose-binding lectin; MASP, mannose-binding-lectin-associated serine 
proteases. Adopted from Flyvbjerg, 2010. 
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Upon activation, complement works on opsonization of the pathogen, chemotaxis 
and phagocyte activation. Complement also directs pathogen lysis via the membrane 
attack complex formation (Heitzeneder et al., 2012). 
2. The promotion of (complement-independent) opsonophagocytosis:  
An important function common to collectin group is to up-regulate the expression 
of cell surface phagocytic receptors. For example MBL increase the expression of 
Scavenger Receptor A on Kupffer Cells (liver macrophage) enhancing their ability to 
phagocytize lipid A, an active moiety of LPS, Staphylococcus aureus, and 
Escherichia coli (Ono et al., 2006).   
Thus, MBL can opsonize the microbes directly through its carbohydrate-binding 
domain and with phagocytes through its collagen like domain (Tsutsumi et al., 
2005). This is along with its indirect opsonizing ability via lectin pathway of 
complement activation (Figure 12) (Ono et al., 2006; Macdonald et al., 2010).  
3. The removal of apoptosis products: 
MBL interacts (Figure 12) with CD 91 and calreticulin receptors on the surface of 
macrophages facilitating apoptotic and necrotic cell phagocytosis. MBL recognizes 
exposed terminal sugars of cytoskeletal proteins on their surfaces. CD 91 receptor is	  
highly expressed on the surface of human macrophages and is involved in the 
recognition and phagocytosis of more than 30 different ligands. This occurs via the 
collagenous region of MBL binding to the calreticulin/CD-91 complex on phagocytes, 
resulting in the ingestion of the apoptotic cell (Duus et al., 2010; Heitzeneder et al., 
2012). 
 
 
Functions of MBL. Figure 12: 
interact with The trimeric MBL subunits 
tail -receptors via the collagenous
domains. MBL recognizes and binds to 
-microorganism surface mannose and N
acetylglucosamine sugars activating 
lectin pathway. Moreover, MBL binds to 
both apoptotic cells and phagocytes, 
	  .f apoptotic cellspromoting the uptake o
Adopted from Tsutsumi et al., 2006.	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4. The modulation of inflammation:  
Mannose binding lectin was primarily identified as complement system activator 
on binding the pathogen carbohydrate moieties (Jack et al., 2001). With more 
elaborate research its function as immune response regulator and its anti-
inflammatory property protecting the body against excessive – unneeded- immune 
responses that may cause excess tissue damage (Wang et al., 2011a; Downing et al., 
2003; Downing et al., 2005; Wang et al., 2011b).  
MBL affects cytokine secretion in concentration dependent manner; at low levels 
MBL increases TNF α, IL 6 and IL 1 liberation from monocytes in vitro and 
decreases their release at high concentrations; (Jack et al., 2001). 
MBL not only interacts with apoptotic cells but also to different cells expressing 
normal self-patterns. MBL ability to interact with immune cells was discovered first 
then the nature of receptors recognize it was identified. MBL can bind to monocyte 
derived dendritic cells (moDcs) especially the immature ones (Downing et al., 2003). 
Thereafter, Downing and coworkers proved the binding of MBL to other immune 
cells e.g. monocytes, B lymphocytes and natural killer cells. Such interaction was 
inhibited in serum suggesting that it happens in the extravascular spaces at sites of 
inflammation and has anti-inflammatory and tolerogenic effect. So they suggested 
that MBL existence act as a disease modifier (Downing et al., 2005). Then Shimizu 
and coworkers proved that MBL and other members of collectins family bind to 
TLR4, CD14 and MD-2 receptors (Shimizu et al, 2009).  
MBL interaction with immune cells modulates inflammatory response. MBL 
recognizes and binds to the peptidoglycan portion of the Gram positive bacterial cell 
wall and modulates the macrophage response to it (Nadesalingam et al., 2005). MBL 
inhibits peptidoglycan induced TNF-α secretion and enhances IL-8 – a chemokine - 
secretion. MBL null mice died of septic shock in response to the S. aureus infection. 
The induced excess tissue damage was attributed to the elevated levels of TNF-α and 
IL-6 in their blood (cytokine storm) (Shi et al., 2004). MBL down-regulates 
macrophage-mediated inflammation (reduced TNF-α and IL-6) while enhancing 
phagocytosis (enhanced IL-8) in response to gram positive bacterial wall 
peptidoglycan (Nadesalingam et al., 2005). MBL clusters the lipoteichoic acid of S. 
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aureus and presents it to TLR2/6 heterodimer within phagosomes inside the 
macrophage enhancing TLR 2 signaling pathway (Ip et al., 2008). MBL binds to and 
inhibits signaling of TLR3, TLR9 & TLR4 (Liu et al., 2014; Tang et al., 2015; 
Wang et al., 2011a) 
Another aspect of MBL role in inflammatory response has been studied in skin 
response to injury. The MBL null mice have abnormal response to burn (thermal 
injury) with reduced sloughing of eschar (dead skin) and interestingly abnormal 
epidermal acanthosis compared to wild type mice (Møller-Kristensen et al., 2007; 
Takahashi, 2011). 
MBL Deficiency 
MBL deficiency is considered one of the commonest immune deficiencies. 
Affected population suffers increased susceptibility to infection e.g. Cutaneous 
infections (Dommett et al., 2006). The prevalence rate of MBL mediated immune 
deficiency has been varied between 5% – 30% of the population (Takahashi, 2011).  
Deficiencies of the MBL-MASP pathway have been associated with recurrent and 
serious infections, autoimmunity, atopic disease, recurrent miscarriage and 
cardiovascular pathology (Worthley et al., 2005). 
MBL replacement therapy 
MBL replacement therapy (Table 1) has been tested both in human and in animal 
model of diseases. MBL was replaced either in a purified form out of human plasma 
or a recombinant human form. Both forms have been verified to be safe and tolerable 
for human use without anti-MBL antibodies production (Petersen et al., 2006; 
Valdimarsson et al., 2004; Bang et al., 2008). 
 In human, MBL replacement therapy was given for MBL deficient pediatric 
cancer patients with chemotherapy induced neutropenia. This replacement was safe 
(Frakking et al., 2009) and successful in restoring circulating MBL level along with 
partial recovery to opsanophagocytosis function which was explained by partial loss 
of MBL complement activation function during purification, the lack of phagocytes 
after chemotherapy and presence of other genetic alterations affected another points in 
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the alternate pathway of complement activation (Brouwer et al., 2009; Garred et al., 
2002). 
In mice, MBL substitution rescued the MBL knockout (KO) mice burnt and 
infected with Pseudomonas aeruginosa from death (Møller-Kristensen et al., 2006). 
MBL reconstitution also improved the survival of MBL KO mice infected with 
Staphylococcus aureus from 0 % survival in MBL KO to 45% after MBL substitution 
(Shi et al., 2004). rhMBL substitution also rescued Ebola virus infected mice 
(Michelow et al., 2011).  
Table 1: MBL replacement Therapy 
 Model  MBL Type  Dose  Method of 
administration  
Wang et al., 
2011 a  
THP1 cell line 
(Human 
monocytic cell 
line)  
pdMBL*  15 µg/ml  
 
Incubation  
Wang et al., 
2011 b  
Peripheral 
blood 
monocyte 
derived 
dentritic cells  
pdMBL  0, 1, 10 or 20 
µg/ml  
Incubation  
Liu et al., 
2014  
Peripheral 
blood 
monocytes & 
monocyte 
derived 
dendritic cells  
pdMBL  10 µg/ml  Incubation  
Tang et al., 
2015  
Peripheral 
blood 
monocytes  
pdMBL  10 µg/ml  Incubation  
Zhou et al., 
2010  
Human 
primary 
embryonic 
kidney cell 
line (293T) & 
Huh-7.5 cell 
pdMBL  0.1, 0.3, 1, 3, or 
10 µg/ml  
 
Incubation  
rhMBL** 
(R&D)  
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 Model  MBL Type  Dose  Method of 
administration  
lines  
Li et al., 2012  Neutrophil 
2*106 cell/ml  
rhMBL 
(R&D)  
2.5, 5, 10 µg/ml  Incubation  
Shi et al., 
2004  
C57bl Mice  rhMBL  
NatImmune  
 
75 µg/ mice/ d for 
3 days in 200 µl 
saline  
Intraperitoneal  
Michelow et 
al., 2011  
C57bl Mice  rhMBL 
NatImmune  
*75 
µg/mouse/12h for 
10 d = 4.3 mg/kg  
*350 
µg/mouse/12h for 
10 d = 20 mg/kg  
Intraperitoneal  
Møller-
Kristensen et 
al., 2006  
C57bl Mice  rhMBL  
NatImmune  
 
 
75 µg/ mouse in 
200 µl saline at 12 
and 2 h before and 
24 h after the burn 
injury.  
Intraperitoneal  
Frakking et 
al., 2009  
Human  pdMBL  0.2 mg/kg/3d  
0.3 mg/kg/4d  
 
Infusion  
Bang et al., 
2008  
Human  pdMBL  Healthy: 
6mg/week for 3 
weeks  
Septicemic: 
0.2mg/kg/ week 
or twice weekly  
Infusion  
Valdimarsson 
et al., 2004  
Human  pdMBL  6mg/ week for 3 
weeks  
Infusion  
Petersen et al., 
2006  
Human  rhMBL 
NatImmune  
0.01, 0.05, 0.1, 
and 0.5 mg/Kg 
Infusion  
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 Model  MBL Type  Dose  Method of 
administration  
once  
0.1, 0.3 mg/Kg/3d  
Garred et al., 
2002  
Human  pdMBL  6mg/3d  Infusion  
* pdMBL; Plasma derived MBL. ** rhMBL; recombinant human MBL. 
So, MBL role has been upgraded from being just a pattern recognition molecule to 
a master innate immune response regulator interacting with other key player of the 
system e.g. TLRs (Downing et al., 2005). 
At the inflammatory loci strong immune stimulation is most needed one to several 
days post infection. MBL though an acute phase reactant, presents at high 
concentration at inflammatory loci, it suppresses the monocytoid cell function. This is 
a desirable homeostatic mechanism to achieve a sterilizing but not self-damaging 
immune response. MBL interacts with autologous immune cells through receptors as 
TLRs enhancing phagocytosis and at the same time preventing excessive cytokine 
release and tissue damaging; tuning the immune response to injury avoiding the 
excessive tissue damage as for example induced by LPS; LPS tolerance (Wang et al., 
2011a).  
It is important to take in consideration that MBL through its role in distinguishing 
self from non-self and thereby elimination of invading pathogens, and its role in the 
clearance of abnormal self-components, particularly apoptotic cells guard against 
autoimmunity. On the contrary, deficient MBL could cause a defect in clearing dying 
cells and immune complexes, resulting in accumulation of hazardous self-components 
which increase the risk of dysregulated immune responses (Downing et al., 2005). 
	  
k- Toll like receptors: 
Toll like Receptors (TLRs) is another important component of innate immune 
response. A family of pattern recognition receptors (PRPs) recognize distinct, 
conserved microbial parts and aid cells to recognize self from non-self in immune 
activation (Hari et al., 2010; Pandey and Agrawal, 2006; Parker et al., 2007). Both 
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exogenous and endogenous patterns are recognized by TLRs (Connolly and O’Neill, 
2012; Pandey and Agrawal, 2006; Parker et al., 2007). Lipopolysaccharide (LPS), 
flagellin, lipopeptides, viral double-stranded RNA (dsRNA) and bacterial DNA are 
pathogen associated exogenous patterns. Endogenous patterns include heat-shock 
proteins, beta defensins, hyaluronic acid, fibronectin, fibrinogen, high mobility group 
box1 (HMGB1), heparin sulphate. According to their site in the cell TLRs are 
classified into:  
I- Cell surface TLRs.  & II- Intracellular TLRs found on intracellular 
organelles membranes as endososmes. 
(Connolly and O’Neill, 2012; Pandey and Agrawal, 2006; Parker et al., 2007)  
 TLR 4 is an example of cell surface TLRs. It acts as homodimer and binds the LPS 
moiety in bacterial cell wall and viral proteins (Connolly and O’Neill, 2012). 
Recently direct binding of MBL with TLR4 was proved (Wang et al., 2011 a). Other 
cell surface located TLRs are TLR2, TLR5, TLR6, TLR10. TLR2 heterodimerizes 
with TLR1 or TLR6 recognizing lipoteichoic acids, lipoproteins and 
lipoarabinomannan moieties (Connolly and O’Neill, 2012; Pandey and Agrawal, 
2006; Parker et al., 2007). Intracellular TLRs are found embedded in membranes of 
vesicles as endosomes, lysosomes endoplasmic reticulum and endolysosomes. 
(Connolly and O’Neill, 2012)  
Of intracellular TLRs (Figure 13) are TLR3, TLR7 & TLR8. TLR3 recognizes 
double stranded RNA. TLR 7 & 8 recognize single stranded RNA and 
imidazoquinoline derivatives e.g. imiquimod which is used as a drug against viral skin 
infections and skin precancerous and cancerous lesions (Hari et al., 2010).  
 
 
 
 
 
Figure 13: Site and Signaling pathway of TLRs inside the cell. 
TLR1, 2, 4, 5, 6, &10 embedded in cell membrane and TLR3, 7, 8, & 9 on endosomal 
wall. Adopted from Hari et al., 2010.	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Toll like Receptors signaling pathways: 
 TLRs are expressed on different sets of cells immune and non-immune cells 
(Figure14). In the skin different cells express TLRs, in the epidermis keratinocytes, 
melanocytes and Langerhans cells express TLRs. In the dermis, many cells express 
them including macrophages, dendritic cells, lymphocytes and others (Hari et al., 
2010).  
     When TLRs binds to the activating moiety, they start one of two intracellular 
signaling pathways (Akira &Takeda, 2004; Shinya et al., 2012):	   
I. MyD88 dependent (myeloid differentiation factor 88) signal ending in NF-
κB release from the inhibitory effect of inhibitor of κB (IκB) proteins with 
induction of IL 6, IL 1, TNF α, and IL 8 gene expression (Pandey and 
Agrawal, 2006; Parker et al., 2007).  
II. TRIF mediated pathway (Toll IL-1 receptor (TIR) domain containing 
adaptor inducing IFN-β) This non MyD88 dependent pathway leads to 
both the induction of NF-κB and type 1 IFN (Interferon) liberation (Parker 
et al., 2007; Pandey and Agrawal, 2006).   
 
Figure 14: Distribution of TLRs in the skin. 
(Connolly and 
O’Neill, 2012) 
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Skin cross section showing keratinocytes and other epidermal cells express different 
TLRs as melanocytes, Langerhans cells, and Merkel cells. Adopted from Hari et al., 
2010 
Inhibitors of TLR signaling pathway have been identified as IRF-4 (Interferon 
regulatory factor) (Parker et al., 2007). Recently, MBL has been identified as another 
inhibitor of LPS induced TLR4 activation of NF-κB (Wang et al., 2011a). 
Toll like Receptors functions: 
Upon activation via TLRs, immune cells initiate phagocytosis, killing of 
pathogens, various chemokine & cytokine production, antigen presentation to T cells 
and leukocyte activation, thereby initiating adaptive immune response (Hari et al., 
2010).	   
1. Control of innate immune response:  
So the primary functions of TLRs is the recognition of PAMPs and the induction 
of innate immune system; antimicrobial peptides and proteins secretion along with 
activation of macrophage with production of various cytokines (IL-1β, IL-6, type I 
INFs and TNF-α) and chemokines (Pasare &Medzhitov, 2004).  
2. Control of adaptive immune responses:  
Another function of TLRs is the control of T cell activation. As already known for 
T cell activation the TCR (T cell Receptor) binds the antigens of microbes presented 
in the MHC molecules of APCs, however this binding to be functioning need the 
presence of co-stimulatory CD 80/CD 86 molecules on the surface of APCs. The 
induction of these co-stimulatory molecules on APCs i.e. immature DCs is the 
responsibility of TLRs. So the engagement of TLRs on DCs in vivo is required to 
induce T cell priming. This function of TLRs is very important in preventing the 
improper T cell recognition of self-epitopes and subsequently the development of 
autoimmune disease (Pasare &Medzhitov, 2004).  
Toll like Receptors also release the T cells from the suppressor effect of T 
regulatory cells via the secretion of IL-6, however this release is balanced to ensure 
proper response to invading pathogens without excessive T cell activation and tissue 
damage (Pasare &Medzhitov, 2004).  
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It is important to notice that despite TLRs main function is to induce protective 
immune responses, under some circumstances, activation of them may end up with 
autoimmune disease (Pasare &Medzhitov, 2004). 
Toll like receptors and Psoriasis: 
TLRs are expressed in both immune and non-immune cells. Monocytes and 
dendritic cells are examples of immune cells highly responsive to TLRs and their 
activating moieties (Hari et al., 2010; Parker et al., 2007; Pandey and Agrawal, 
2006). When TLRs are stimulated in monocytes, various types of cells are recruited 
e.g. dendritic cells, T lymphocytes and natural killers. TLRs also contribute in 
intercellular communication so that optimal cell response is ensured (Hari et al., 
2010). 
Cells in tissues with barrier functions (in contact with outer environment) e.g. skin, 
genitourinary tract, GIT and respiratory system express TLRs, keratinocytes and 
melanocytes of the skin are examples of non-immune cells expression TLRs (Hari et 
al., 2010; Pandey and Agrawal, 2006; Parker et al., 2007). 
Toll like receptors have been implicated in psoriasis development (Jiang et al., 
2013). TLR 9 is involved in the activation of pDCs by the LL37/self DNA complex 
ending in type I INF release and subsequent myeloid DCs maturation and auto-
reactive T cells activation with continuous feedback loop (Hari et al., 2010).  
TLR9 is upregulated in psoriatic skin (Morizane et al., 2012). Both TLR5 and 
TLR9 are regulated by the transforming growth factor-α (TGF-α) an important growth 
factor highly expressed in psoriasis. TGF-α, a keratinocyte growth and stimulating 
factor, binds to EGF receptor (EGF-R) on keratinocytes surface activating them. 
TGF-α increases TLR5 and TLR9 mRNA expression and subsequently increases 
proinflammatory cytokine, IL-8, and the antimicrobial peptide, hβD-2 production 
(Miller et al., 2005). Both LL-37 & TLR9 are over expressed in psoriasis, LL-37 
increases expression of TLR9 and enhances its binding to CpG and genomic DNA 
(Morizane et al., 2012).   
TLR7 and 8 has been implicated in psoriasis pathogenesis as their agonist, 
Imiquimod, exacerbates psoriasis and induces psoriasiform lesions in mice (Van der 
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Fits et al., 2009). TLR7 & 9 are expressed on plasmacytoid DCs (pDCs) whereas 
TLR8 is expressed on myeloid DCs (Hari et al., 2010; Jiang et al., 2013). Jiang and 
coworkers used antagonists to TLR7, 8&9 as therapy for psoriasis like lesions 
induced by IL23 injections in mice. They reported inhibition in Th1 and Th17 
responses (Jiang et al., 2013). Antagonists of TLR7, 8 & 9 have been used in 
preclinical models for treatment of autoimmune diseases as arthritis, lupus and uveitis 
(Jiang et al., 2013). Thus, TLR antagonism is a promising target for psoriasis 
treatment (Jiang et al., 2013). 
TLR3 signaling has been recently associated with enhanced keratinocyte 
expression of the common p40 subunit of both IL23 & IL12 which link TLR3 with 
wound healing and probably psoriasis (Ramnath et al., 2015).    
TLR4 and TLR2 have been linked to psoriasis development. TLR4 expression in 
the skin was higher in psoriasis than normal skin (Garcia-Rodriguez et al., 2013; 
Seung et al., 2007). In another study Baker and coworker showed that in psoriatic 
lesional epidermis, TLR2 was highly expressed on upper epidermal keratinocyte more 
than on the basal layer keratinocytes (Baker et al., 2003; Garcia-Rodriguez et al., 
2013). Moreover, Heat shock proteins e.g. HSP60 heavily expressed by keratinocytes 
of psoriasis, trigger TLR4 on APCs leading to maturation and secretion of TNF-α and 
IL-12. Furthermore, the keratinocyte derived fibronectin act on TLR4 pathway of 
APCs (Langerhans cells) causing their maturation, TNF α and IL 12 liberation, along 
with antigen presentation to autoreactive T cells (Gaspari, 2006; Hari et al., 2010). 
The upregulated AMPs in psoriasis, S100A8 and S100A9, are endogenous activators 
of TLR4 (Garcia-Rodriguez et al., 2013). Furthermore, antikeratin 16 monoclonal 
antibodies increase the expression levels of TLR 2, TLR4 and NF-κB nascent 
polypeptide-associated complex. Anti-keratin 16 antibodies are highly detected in the 
serum of psoriasis patients (Hari et al., 2010). 
On the systemic level, TLR4 & to a lesser extent TLR2 gene expression were 
higher in psoriatic patients' peripheral blood monocytes than in control. This could 
infer a role of TLR4 & TLR2 in the pathological systemic inflammatory status in 
psoriasis patients which leads to and ⁄ or aggravates other associated chronic 
inflammatory diseases e.g. cardiovascular accidents, diabetes mellitus (Garcia-
Rodriguez et al., 2013). 
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Topical and systemic retinoids have anti-inflammatory activity through inhibition 
of TLR2 signaling which may be part of the mode of actions of retinoids in psoriasis 
treatment (Hari et al., 2010; Tenaud et al., 2007). Retinoids have also been proved 
to have anti-inflammatory & immunomodulatory activity through their inhibitory 
effects on TLR4/ NFκB pathway blocking various cytokine secretion including IL1β, 
IL 6, IL12 and TNF-α (Kim et al., 2013; Gu et al., 2010). 
It is interesting to know that monomethyl fumarate (fumaric acid ester), an 
immunotherapeutic for psoriasis, greatly inhibits LPS signaling via TLR4 in dendritic 
cells, inhibits NF-κB activation, lowers IL 12 & IL 10 production, and modulates 
monocytes-derived DC polarization i.e. fumaric acid ester has the same effect of MBL 
on LPS induced TLR4 signaling pathway as proved by Wang and coworkers (Hari et 
al., 2010; Wang et al., 2011a). 
To sum up TLRs are critical component of innate immune system and are involved 
with dendritic cells and other APCs in priming the adaptive immune response. TLRs, 
as part of immune system, are involved in psoriasis development and their antagonists 
proven to have anti-psoriatic effect.  
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Aim of the work 
  In this study we aimed at establishment of psoriasis model in C57Bl mice 
background using Imiquimod daily topical application. We tested the best schedule 
for induction and maintenance of disease. We aimed at exploring the best methods for 
assessment of disease induction and progression using clinical, dermoscopic, 
histopathological and molecular techniques. Establishment of this model paves the 
way for testing different potential therapeutics for psoriasis along with exploring the 
disease pathogenesis itself.  
Following the establishment of this psoriasis model, we proceeded to use it for 
testing the efficacy of MBL, an immune response modifier, in treating this 
psoriasiform induced inflammation. The effectiveness of MBL was evaluated on 4 
levels; clinically dermoscopically, histopathologically and eventually the molecular 
pathways involved in the response were explored. 
This work introduces a new potential therapeutic for psoriasis. This potential 
therapeutic offers blocking of an early step in the disease pathogenesis without the 
side effects that complicate other therapeutics including lymphoma development, 
reactivation of TB infection or being contraindicated in HIV or HCV patients. 
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Materials And Methods 
Psoriasis animal model: 
Eight to 11 week female C57BL mice were obtained from Theodore Bilharz 
Research Institute, Cairo. Animals were maintained and handled in accordance with 
NIH guidelines for the care and use of laboratory animals. Induction of psoriasis was 
executed as previously reported with few modifications (Chamcheu et al., 2016; Van 
der Fits et al., 2009). In brief, the back of each mouse was shaved (area 2 X 2 cm2 
approx.) and the remaining hair was removed using a depilatory cream (Veet®; 
Reckitt Benckiser, UK). Forty eight hours later animals were evaluated clinically with 
the aid of DermLite DL3® dermoscope (3Gen, Inc., USA). Animals were sampled 
(skin & spleen) for further analysis for histopathologic evaluation and gene 
expression analysis serving as normal (negative control group). Each mouse received 
a daily topical dose of 62.5 mg (1/4 sachet) of Imiquimod (IMQ) cream (5%) (Aldara; 
3M Pharmaceuticals) on the depilated back skin for 5 consecutive days, equivalent to 
a daily dose of 3.125 mg of the active compound. Following induction animals were 
divided into 2 groups one received the MBL treatment (n = 6) and the other received 
phosphate buffer saline (PBS) injection as control (n = 7). Both groups continued to 
receive same IMQ dose for the rest of treatment period (Figure 15). 
 
Days	   -­‐1	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	  
	   Hair 
removal 
	   IMQ induction alone IMQ + (MBL/PBS) Final sampling 
day 
 
 
MBL treatment: 
Recombinant mouse MBL2 was purchased from R&D Systems (Minneapolis, 
MN), and was reconstituted according manufacturer recommendation at 100 µg/ml of 
sterile PBS and kept at – 80 0C until injection. On the day of injection 20 µg (200 µl) 
were further diluted in an 800 µl PBS and each mice received 150 µl intralesional 
injection in the back using Hamilton® syringe (Sigma-Aldrich, USA), for 4 
Figure 15: Schedule Of Psoriasis induction & treatment. 
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consecutive days. So the mice received daily dose of 3 µg of recombinant mouse 
MBL. Control mice received same volume of sterile PBS (150 µl) daily. On the fifth 
day of treatment skin & spleen samples were collected. 
Clinical Evaluation: 
Mice were evaluated clinically at 4 time points; a) Before induction on day 1. b) 
Mid induction phase on day 3. c) Before start of treatment on day 6 and finally, d) at 
the end of treatment at day 10. Clinical evaluation included weighing of mice, 
measuring thickness of back skin using electronic digital caliper (Titan, USA), 
assessment of extent of induction using erythema scaling and thickness score 
previously reported (Chamcheu et al., 2016; Van der Fits et al., 2009). Erythema, 
scaling and thickness were given a score 0 - 4 (0; none, 1; mild, 2; moderate, 3; 
marked, 4; severe). A red panel was used for objective assessment of erythema.  
Dermoscopic Evaluation: 
For more precise evaluation of the psoriasis induction and the response to 
treatment, DermLite DL3® dermoscope was used. Dermoscope is a hand held device 
with magnification range 10 – 40 x for better visualization of surface skin and deeper 
down to dermal vessels and pigment. It was used to assess the mice at the same 
interval used for clinical evaluation, Figure 16. To our knowledge this is the first time 
dermoscopy is used in experimental dermatology for psoriasis induction and follow 
up of therapeutic response. According to the known dermoscopic criteria of psoriasis 
(Lallas et al., 2012; Micali et al., 2011), the induction of psoriasis was ascertained by 
detection of dotted (glomerular) vessels distributed homogenously on the lesion, 
erythematous background and silvery white scales. The lesions were examined with 
non polarized light for evaluation of scaling followed by polarized light and finally 
with alcohol interface for better visualization of vascular pattern. We developed a 
scoring system to assess the response to therapy as illustrated in Table 2. The Scaling 
extent is given a score 0-3 with 0 = no changes, Figure 17, 1 = mild, Figure 18, 2 = 
moderate, Figure 19, and 3 = severe, Figure 20. Also the erythema and blood vessels 
is given similar score from 0-3 Figures 21- 24. The total score for each mouse is from 
0-6.  
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Table 2: Scoring table for dermoscopic evaluation of therapeutic response: 
 None (0) Mild (1) Moderate (2) Severe (3) Total score 
Back ground 
erythema & 
Vessels 
    
 
Scales     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: DermLite DL3 Dermoscope 
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X 40 
Figure 18: Scale grade 1  
Figure 17: Scale grade 0 
X 10 
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Figure 19: Scale grade 2  
X 40 
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Figure 20: Scale grade 3  
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Figure 22: Erythema& vessel grade 1  
Figure 21:	  Erythema&	  vessel	  grade	  0	  	  
X 40 
X 40 
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Figure 23:	  Erythema	  &	  vessel	  grade	  2	  	  
X 10 
Figure 24:	  Erythema	  &	  vessel	  grade	  3	  	  
X 10 
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Histological Evaluation & Epidermal Thickness Assessment: 
For histological examination, 5 ml punch biopsy from the back skin was 
immersed in 10% formalin. Samples were then embedded in paraffin wax, and 
sections were processed for H&E staining. The slides were examined under LEICA 
DM 1000 microscope (LEICA Microsystems, Wetzlar, Germany) with 10X & 40X 
magnification. Images under 10X magnification were further assessed using Image J 
(Kim et al., 2015). To determine the average epidermal thickness 10-15 shots for 
each slide were taken then 6-8 readings /shot for the epidermal thickness (a straight 
perpendicular line is drawn from the basal layer to the upper stratum corneum) to 
assess the average epidermal thickness for each mouse. 
Gene Expression analysis: 
Skin samples were stored in RNAlater® (AMBION, Inc., USA) overnight then 
removed from it and kept at – 80 o C till total RNA was extracted using RNeasy Mini 
kit  (Qiagen, Valencia, CA). Skin samples were first homogenized in 700 µl TRizol 
then 140 µl of chloroform was added. Centrifugation for 15 min at 12,000 x g at 4°C 
was followed for phase separation followed by column extraction according to 
manufacturer protocol. RNA (0.5µg) was reverse transcribed using the RevertAid 
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific Inc, Waltham, 
Figure 24, continued: Erythema & vessel grade 3  
X 40 
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Massachusetts, USA). Quantitative real-time PCR was carried out using StepOnePlus 
PCR system (Invitrogen), and hypoxanthine-guanine phosphoribosyltransferase 
(Mm00446968_m1) served as endogenous control to calculate the relative amount of 
gene expression. Relative quantity of mRNA was calculated as respect to the mean of 
normal group, which is set to 1. TaqMan® ready made Gene expression assays for 
mouse IL6 (Mm00446190_m1) and IL12a (Mm00434169_m1) were measured.	  	  
Statistical analysis: 
Quantitative data were statistically represented in terms minimum, maximum, 
median, mean and standard division (SD). Comparison between difference groups in 
the presents study was done using Independent samples T-Test for comparing two 
parametric groups, and using Mann-Whitney Test for comparing two nonparametric 
groups, and One-way ANOVA Test was used when comparison between more than 
two parametric groups with (LSD) or (Dunnett t Test) as multiple comparison tests, 
and Kruskall-Wallis Test was used when comparison between more than two 
nonparametric groups, and using Paired Samples T-Test for comparing two paired 
parametric groups, and using Wilcoxon Signed Ranks Test for comparing two paired 
nonparametric groups. 
 Qualitative data were statistically represented in terms number and percent. 
Comparison between difference groups in the presents study was done using Chi-
Square Test. 
 A probability value (p value) less than or equal to (0.05) was considered 
significant and CI 95%. All statistical calculations were done using computer program 
SPSS (Statistical Package for Social Science) statistical program version (16.0). 
Graphs were done using Microsoft Excel program version 2010.	  
	  	  
	   Results 	  
	   	  
58	  
Results 
I- Establishment of Psoriasis Mouse Model: 
Imiquimod (Aldara ®, 5% Cream, 3M, USA) was applied daily for 6 days on the 
shaved back of mice. This successfully induced psoriasis-like lesions. 
 
a.  Imiquimod induces psoriasis-like lesions in mouse skin clinically: 
The skin of the back of the mice was shaved and assessed 1 day before Imiquimod 
application and at 3 & 6 days after start of Imiquimod application. Skin started to show 
signs of inflammation in the form of erythema, scaling and increased thickness. The 
scoring of each parameter and the total score differed significantly between mice at day 0 
and on day 6 as illustrated in Table 3 and Figure 25. These Psoriasis-like or psoriasiform	  lesions were consistent with Psoriasis pathology seen in human.  
Table 3: Clinical score of mice after Imiquimod application: 
Parameters Groups N* Min. Max. Median Mean ± S.D. P value 
Erythema Normal 27 0.00 1.00 0.00 0.11 ± 0.32 0.001 
Imq* 24 2.00 4.00 3.50 3.33 ± 0.76 
Scaling Normal 27 0.00 1.00 0.00 0.19 ± 0.40 0.001 
Imq* 24 2.00 4.00 3.00 3.38 ± 0.65 
Thickness 
Normal 27 0.00 2.00 0.00 0.19 ± 0.48 
0.001 Imq* 24 1.00 4.00 4.00 3.38 ± 1.01 
Total Normal 27 0.00 3.00 0.00 0.48 ± 0.80 0.001 Imq* 24 7.00 12.00 10.00 10.08 ± 1.72 
*Imq: 6 days Imiquimod induction 
**N: Number of mice 
Skin fold thickness increased significantly with development of psoraisiform lesions 
(P= 0.001), Table 4. 
Table 4: Skin fold thickness after Imiquimod application: 
Parameters Groups N** Min. Max. Median Mean ± S.D. P value 
Skin fold 
thickness 
(mm) 
Normal 20 0.43 0.80 0.63 0.63 ± 0.09 
0.001 Imq* 24 0.70 1.80 1.04 1.14 ± 0.33 
*Imq: 6 days Imiquimod induction 
**N: Number of mice 
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Figure 25: Successful induction of Psoriasis in mouse model. A) Graphic representation 
of progression of psoriasiform lesions from normal to 3 days and 6 days after Imiquimod 
application where erythema, scaling thickness has increased significantly (P = 0.001). B) 
Normal shaved back skin of mouse with 0 score on erythema scaling, thickness and total 
score. C) Psoriasis development with 4 score on erythema, scaling thickness and total 
score of 12. 
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b. Imiquimod induces psoriasis-like lesion in mouse skin dermoscopically: 
Psoriasis induction was evaluated by dermoscopy. The characteristic dermoscopic 
features of psoriasis previously reported were evaluated and included in a scoring system 
to evaluate the induction and response to therapy. Two parameters were assessed; the 
dotted vessel and the background erythema component and the scaling component. The 
changes were given a score from 0 to 3 according to the severity of change. Scaling has 
increased significantly when compared to normal skin. The skin was thick, red with 
dotted blood vessels. Imiquimod-induced skin has significantly differed from normal skin 
regarding each of the two components and the total score (P = 0.001) Table 5 and 
Figure 26. Normal dermoscopic appearance was very thin transparent skin with long 
linear blood vessels easily seen on 10X without scales. The skin is very thin, it reflects 
the color of underneath tissues and when elevated to form a fold it is of skin colored, 
(Figure 26). 
 
Table 5: Dermoscopy Score in normal and Imiquimod induced psoriasiform lesions. 
*Imq: 6 days Imiquimod induction 
 
Parameter Groups N Min. Max. Mean ± S.D. P value 
Erythema 
& Blood 
vessel 
Normal 27 0.00 1.00 0.07 ± 0.27 
0.001 
Imq* 16 1.00 3.00 2.50 ± 0.82 
Scaling Normal 27 0.00 1.00 0.15 ± 0.36 0.001 
Imq* 16 1.00 3.00 2.56 ± 0.63 
Total 
Normal 27 0.00 2.00 0.22 ± 0.51 	  
Imq* 16 3.00 6.00 5.06 ± 1.29 0.001 
	  	  
	   Results 	  
	   	  
61	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Dermoscopy of Imiquimod induced psoriasiform lesions. A) Normal mouse 
with thin transparent skin, linear branching vessels and skin colored fold. B) Induced skin 
with scaling and dotted vessel distributed on the lesion 10X. 
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Figure	  26,	  continued:	  Dermoscopy	  of	  Imiquimod	  induced	  psoriasiform	  lesions.	  C)	  Induced	  skin	  with	  white	  silvery	  scale	  and	  dotted	  vessels	  40X.	  D)	  White	  silvery	  scale	  using	  non-­‐polarized	  light	  mode.	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Figure 26, continued: Dermoscopy of Imiquimode induced psoriasiform lesions.  E) 
Dotted vessels using polarized light mode. 
 
c. Imiquimod induces psoriasiform histopathological changes in mouse skin. 
Imiquimod treated skin showed acanthosis, hyperkeratosis and parakeratosis. In the 
dermis there is perivascular inflammatory infiltrate. The epidermal thickness has 
significantly increased (P = 0.001) from (17.7 µm + 5.7µm) in normal skin to (83.4 µm + 
1.9 µm) in induced skin, Table 6 & figure 27. 
 
Table 6: Imiquimod significantly increased epidermal thickness: 
Groups N Min. Max. Median Mean ± S.D. P value 
Normal	   13	   11.34	   27.50	   15.39	   17.77	  ±	  5.74	   0.001 
Imq*	   5	   80.49	   85.59	   84.12	   83.49	  ±	  1.92	  
 *Imq: 6 days Imiquimod induction 
**N: Number of mice 
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Figure 27: Psoriasiform changes in Imiquimod induced skin. A) Normal back skin of 
mice with thin epidermis, no rete ridges or inflammatory infiltrate. B) Imiquimod induced 
psoriasiform changes with acanthosis, hyperkeratosis& dermal inflammatory infiltrate.  
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Figure27, continued: Psoriasiform changes in Imiquimod induced skin. C) Parakeratosis 
in stratum corneum. D) Dermal lymphocytic inflammatory infiltrate. E) Imiquimod 
increased epidermal thickness. The epidermal thickness of 10X images analyzed using 
Image J showed significant increase in epidermal thickness (P= 0.001) 
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II. Treatment of Psoriasiform lesions using MBL 
MBL is an immune response modifier plays an essential role in fine tuning 
inflammatory responses in the extravascular spaces at site of inflammation.  
a. MBL treated group started to gain weight: 
MBL treated mice started to gain weight while PBS control mice continued to lose 
weight (P=0.01) Table 7, Figure 28. 
Table 7: Percentage of weight change in MBL & PBS groups  
Parameters	   N**	   Median	   Mean	  ±	  S.D.	   P	  valuea	  
Weight	  
MBL	   6	   11.27	   9.63	  ±	  4.54	  
0.010	  
PBS	   7	   -­‐7.04	   -­‐5.63	  ±	  9.02	  
a P value between MBL and PBS using None-Parametric test (Mann-Whitney Test). 
**N: Number of mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. MBL clinically reverse the imiquimod induced psoriasisform inflammation: 
Intralesional injection of MBL successfully treated the psoriasiform skin lesions 
induced by imiquimod application. The skin of MBL treated mice showed significant 
reduction in all signs of psoriasiform lesions (erythema, scaling and thickness). On the 
other hand the control group (mice received only PBS) didn’t show any significant 
improvement in the psoriasiform lesions compared to their clinical scoring before, Table 
8 & Figures 29, 30 &31.  
Figure 28: Weight change on MBL treatment. MBL group gained weight while PBS 
control group continued to loose weight. 
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Table 8: MBL treats the Imiquimod induced psoriasifrom lesions  
Parameters Groups N** Median Mean ± S.D. P valuea P valueb 
Erythema 
	  
MBL  6 0.00 0.17 ± 0.41 0.001	   0.001	  
PBS 7 3.00 3.00 ± 0.58 0.219	  
Imq* 24 3.50 3.33 ± 0.76 	   	  
Scaling 
MBL 6 1.00 1.00 ± 0.89 0.001	  
0.002	  PBS 7 4.00 3.71 ± 0.49 0.211	  
Imq* 24 3.00 3.38 ± 0.65 	   	  
Thickness 
MBL  6 1.00 1.17 ± 1.47 0.002	   0.036	  PBS 7 4.00 3.14 ± 1.46 0.909	  
Imq* 24 4.00 3.38 ± 1.01 	   	  
Total 
MBL  6 2.00 2.33 ± 1.51 0.001	   0.002	  
PBS 7 11.00 9.86 ± 2.12 0.847	  
Imq* 24 10.00 10.08 ± 1.72 	   	  
a	  P value compared with Imq group using None-Parametric test (Mann-Whitney Test). 
bP value between MBL group and PBS group using None-Parametric test (Mann-Whitney Test). 
*Imq: 6 days imiquimod induction 
**N: Number of mice. 
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Figure 29: MBL improves psoriasiform lesional clinical score. MBL group showed 
significantly reduced clinical score in erythema, scaling, thickness, and total score 
compared to 6 days Imiquimod induction (Imq) scores (P < 0.002). PBS control group 
didn’t show significant variation from Imq group (P > 0.05). MBL group had 
significantly lower clinical score compared to PBS control group (P < 0.05)  
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Figure	  30:	  MBL injections improve Imiquimod induced psoriasis. A) MBL treated 
mouse with almost normal skin with mild scaling without erythema or increased 
thickness. B) PBS control group with marked scaling, erythema and thickening of the 
skin.  
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Figure	  31:	  MBL treatment improves psoriasiform lesions. A) Imiquomod induced 
mouse before MBL treatment. B) Reversal of psoriasiform lesions after MBL treatment. 
C) Imiquimod induced mouse before PBS. D) Same mouse after PBS injection.  
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The skin fold thickness was significantly lower in MBL treated mice compared to 
PBS mice (P = 0.045), Table 9. While MBL treatment reduced the skin fold thickness 
significantly (P = 0.005) PBS received mice didn’t show significant reduction in their 
skin fold thickness compared to 6 day imiquimod induction (P = 0.943), Table 9, Figure 
32. 
Table 9: Skin fold thickness in MBL treated & PBS control group 
Parameters Groups N** Median Mean ± S.D. P valuea 
P 
valueb 
Skin fold thickness 
MBL 6 0.73 0.75 ± 0.17 0.005	   0.045 PBS 7 1.04 1.11 ± 0.36 0.943	  
Imq* 24 1.04 1.14 ± 0.33 	   	  
a	  P value compared with  Imq group using None-Parametric test (Mann-Whitney Test). 
b P value between MBL group and PBS group using None-Parametric test (Mann-Whitney Test). 
*Imq: 6 days imiquimod induction 
**N: Number of mice 
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Figure 32: MBL reduced skin fold thickness.  MBL treatment significantly reduced 
skin fold thickness (P=0.005) from 6 days imiquimod induction (Imq) thickness while 
PBS group didn’t show significant reduction in skin fold thickness (P=0.943). MBL 
treated mice have significantly lower skin fold thickness than PBS control group 
(P=0.045). 
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c. MBL reversed the Imiquimod induced psoriasis on dermoscopic 
examination: 
The improvement of Psoriasiform inflammation was also evident when examined by 
dermoscope with significant reduction (P= 0.001) of scaling, dotted vessels and 
background erythema score in MBL treated group while the PBS control group didn’t 
vary significantly from the start of PBS injections, Table 10 & Figures 33 & 34. 
Table 10: MBL treatment reduces dermoscopy scores. 
Parameters Groups N** Median Mean ± S.D. P valuea 
P 
valueb 
Erythema 
& Blood 
vessel 
MBL  6 0.00	   0.00 ± 0.00 0.001	   0.001	  
PBS 7 2.00	   2.29 ± 0.76 0.399	  
Imq* 16 3.00	   2.50 ± 0.82 	   	  
Scaling 
MBL  6 1.00	   1.00 ± 0.63 0.001	   0.001	  
PBS 7 3.00	   3.00 ± 0.00 0.067	  
Imq* 16 3.00	   2.56 ± 0.63 	   	  
Total 
MBL  6 1.00	   1.00 ± 0.63 0.001	   0.002	  PBS 7 5.00	   5.29 ± 0.76 0.942	  
Imq* 16 6.00	   5.06 ± 1.29 	   	  
a	  	  P value compared with Imq group using None-Parametric test (Mann-Whitney Test). 
b	  	  P value between MBL group and PBS group using None-Parametric test (Mann-Whitney Test). 
*Imq: 6 days imiquimod induced mice 
**N: Number of mice 
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Figure 33: MBL reduced dermoscopic Scoring.  MBL treatment significantly reduced 
dermoscopic changes (Erythema & vessel, Scaling and total score) compared to 6 days 
Imiquimod induction score (P= 0.001) while PBS group didn’t show significant 
reduction on dermoscopic evaluation (Erythema P= 0.399, Scaling P= 0.067 & total 
P=0.942).  
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Figure 34: Dermoscopy of MBL treated mice VS PBS treated group. A) MBL treated 
mouse with no erythema or dotted vessels and with very mild silvery scales B) PBS 
mouse with marked background erythema, dotted vessels and thick silvery scales. 
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d. MBL improved psoriasiform pathologic changes of the skin: 
Microscopic examination of H&E stained sections of MBL treated skin showed 
significant reduction in epidermal thickness (P = 0.001) compared to epidermal thickness 
of 6 days Imiquimod induction. PBS group, on the other hand didn’t differ significantly 
from samples taken at 6 days of imiquimod induction (Imq) (P = 0.064), Table 11, 
Figure 35. Epidermal thickness was significantly reduced in MBL treated mice compared 
to PBS control group, Table 11, Figure 35 & 36 
 
Table 11: MBL treatment reduced epidermal thickness 
Groups N** Median Mean ± S.D. P valuea P valueb 
MBL	   6	   41.76	   42.45	  ±	  4.82	   0.001	   0.001 
PBS	   6	   73.12	   75.79	  ±	  6.85	   0.064	  
Imq*	   5	   84.12	   83.49	  ±	  1.92	   	   	  
a  P value between each group and the Imq group using Multiple Comparison test (Dunnett t Test). 
b  P value between MBL group and PBS group using Parametric test (Independent Samples T-Test). 
* Imq: 6 days of Imiquimod induction 
** N: Number of mice 
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Figure 35: MBL treatment reduces epidermal thickness.  MBL treatment significantly 
reduced epidermal thickness (P = 0.001) measured by 10X microscope with Image J 
analysis. On the other hand PBS didn’t show significant reduction in epidermal 
thickness (P = 0.064) compared with 6 days Imiquimod mice.  
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Figure 36: Epidermal thickness in MBL & PBS groups. A) MBL treated skin with 
significant reduction in epidermal thickness. B) PBS control group with non-significant 
change in epidermal thickness compared to 6 days Imiquimod mice.  
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e. MBL affected distant areas of skin:  
Sites directly injected with MBL showed slightly better clinical, dermoscopic and 
pathologic scoring than distant areas of skin, however this difference was not statistically 
significant except in total clinical score, Table 12, 13, 14 & 15 Figure 37. 
Table 12: MBL injected sites had similar clinical score as distant areas: 
Parameters	   Groups	   N*	   Median	   Mean	  ±	  S.D.	   P	  valuea	  
Erythema	  
Injected	  area	   6	   0.00	   0.17	  ±	  0.41	  
0.211	  
Distant	  Area	   6	   0.50	   0.67	  ±	  0.82	  
Scaling	  
Injected	  area	   6	   1.00	   1.00	  ±	  0.89	  
0.238	  
Distant	  Area	   6	   2.00	   1.67	  ±	  1.03	  
Thickness	  
Injected	  area	   6	   1.00	   1.17	  ±	  1.47	  
0.434	  
Distant	  Area	   6	   1.00	   1.83	  ±	  1.72	  
Total	  
Injected	  area	   6	   2.00	   2.33	  ±	  1.51	  
0.036	  
Distant	  Area	   6	   4.00	   4.17	  ±	  0.75	  
a	  	  P value between injected area and distant area in Clinical Evaluation MBL using None-Parametric 
test (Mann-Whitney Test). 
*N: number of mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical	  Score,	  4.0	  
0.0	  
0.5	  
1.0	  
1.5	  
2.0	  
2.5	  
3.0	  
3.5	  
4.0	  
4.5	  
injected	  Distant	   Injected	  Distant	   Injected	  Distant	   Injected	  Distanet	  
Erythema	   Scaling	   Thickness	   Total	  
Sc
or
e	  
Clinical	  Score	  
Figure	  37:	  Clinical score for Distant and injected sites in MBL group. Distant area 
don’t show significant difference than the improvement seen in injected sites except in 
the total score (P = 0.036) 
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Table	  13:	  skin	  fold	  thickness	  similar	  in	  MBL	  injected	  sites	  &	  distant	  sites:	  
Parameters	   Groups	   N*	   Median	   Mean	  ±	  S.D.	   P	  valuea	  
Thickness	  
(mm)	  
Injected	  area	   6	   0.73	   0.75	  ±	  0.17	  
0.516	  
Distant	  Area	   6	   0.75	   0.82	  ±	  0.19	  
a	   	  P value between injected area and distant area in skin fold thickness using None-Parametric test 
(Mann-Whitney Test). 
*N:	  Number of mice. 
 
Table	  14:	  Dermoscopic	  scoring	  similar	  in	  MBL	  injected	  sites	  	  &	  distant	  sites:	  
Parameters	   Groups	   N	   Median	   Mean	  ±	  S.D.	   P	  valuea	  
Erythema	   &	  
Blood	  vessel	  
Injected	  area	   6	   0.00	   0.17	  ±	  0.41	  
0.138	  
Distant	  Area	   6	   0.00	   0.67	  ±	  0.82	  
Scaling	  
Injected	  area	   6	   1.00	   1.00	  ±	  0.89	  
0.171	  
Distant	  Area	   6	   1.50	   1.67	  ±	  1.03	  
Total	  
Injected	  area	   6	   1.00	   1.17	  ±	  1.47	  
0.067	  
Distant	  Area	   6	   2.00	   1.83	  ±	  1.72	  
a	  	  P value between injected area and distant area in Dermoscopy using None-Parametric test (Mann-
Whitney Test). 
Table 15: MBL injected sites had similar histopathologic epidermal thickness as 
distant areas: 
Groups	   N*	   Median	   Mean	  ±	  S.D.	   P	  valuea	  
Injected	  area	   6	   41.76	   42.45	  ±	  4.82	  
0.288	  
Distant	  Area	   6	   41.15	   37.58	  ±	  9.50	  
a	  	  P value between Injected area and distant area in epidermal thickness using Parametric test (Independent 
Samples T-Test). 
*N: Number of mice 
 
f. MBL mice had normal splenic Histology: 
Mice continued to receive Imiquimod and PBS showed abnormal splenic pathology 
in the form of expanded white pulp, cellular hyperplasia & macrophage infiltration 
indicting an immune reactivation process of the spleen. These changes were not observed 
in MBL treated mice whose spleen showed normal histology, Figure 38.  
The splenic weight in MBL treated group and PBS control group was significantly 
higher than normal spleen however there wasn’t significant difference between the two 
groups, Table 16, Figure 39. 
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Figure	  38:	  Splenic Histopathology. A) MBL treated mice spleen showing normal white 
pulp. B) PBS control spleen showing cellular hyperplasia &infiltration with 
macrophages. 
Figure	  39:	  Splenic weight. MBL & PBS groups had significantly higher splenic weight 
than normal spleen (P= 0.013, P= 0.001 respectively). Spleen weight is not 
significantly different between both groups (P = 0.221) 
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Table 16: Splenic weight is significantly higher than normal in MBL & PBS groups  
Parameters	   Groups	   N*	   Median	   Mean	  ±	  S.D.	   P	  valuea	   P	  valuec	  
Splenic	  
weight	  
Normal	   9	   87.30	   86.30	  ±	  38.35	   	   	  
MBL	   3	   219.90	   205.60	  ±	  34.08	   0.013	  
0.221	  
PBS	   8	   167.40	   183.33	  ±	  54.31	   0.001	  
a	  	  P value between each group and Normal group using None-Parametric test (Mann-Whitney Test). 
c	  	  P value between MBL group and PBS group using None-Parametric test (Mann-Whitney Test). 
*N: Number of mice 
 
g. MBL treatment altered cytokine expression in the treated skin:  
MBL is immune response modifier secreted at sites of inflammation to fine tune the 
immune response to avoid excess tissue damage. On high concentration, MBL inhibits 
both TLR4 & TLR9 signaling subsequently NFκB dependent secretion of many 
cytokines including IL6 & IL12. IL-6 plays important role in Th17 differentiation, a key 
player in the pathogenesis of psoriasis. It also induces IL-8 secretion and enhances 
neutrophil chemotaxis to skin. Psoriatic patients have higher serum and skin IL-6. Its 
high level in the serum is an indicator of activity and reduction of its level is associated 
with response to methotrexate and UVB therapy in psoriasis (Saggini et al., 2014)  
MBL treatment reduced IL-6 to expression level similar to its level in normal skin on 
the other hand PBS group showed significantly higher expression profile (P = 0.05) than 
both of them, Table 17, Figure 40.  
Table 17: IL-6 Expression Profile: 
Groups N* Median Mean ± S.D. 
Normal 4 0.83 0.91 ± 0.38c 
MBL Group 4 0.91 0.97 ± 0.62c 
PBS Group 5 3.39 3.20 ± 1.44ab 
a	   	  Indicates that there is significant difference with Normal group at 0.05 significant level using None-
Parametric test (Mann-Whitney Test). 
b	   	   Indicates that there is significant difference with MBL group at 0.05 significant level using None-
Parametric test (Mann-Whitney Test). 
c	   	   Indicates that there is significant difference with PBS group at 0.05 significant level using None-
Parametric test (Mann-Whitney Test). 
*N: Number of mice. 
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IL12 expression was similar in normal and PBS control group (P=1). MBL group 
had lower expression level than normal and PBS group, however it was statistically 
insignificant, Table 18, Figure 41. 
 
Table 18: IL12 Expression in MBL & PBS: 
Groups N* Median Mean ± S.D. P valuea P valueb P valuec 
Normal 3 	   1.05 ± 0.41 0.083 1 
1 MBL 2 	   0.26 ± 0.05 
PBS 2 	   1.34 ± 1.60 
a P value between Normal and MBL groups 
b P value between Normal and PBS groups 
c P value between PBS and MBL groups 
*N: Number of mice 
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Figure 40: MBL reduced IL6 levels to Normal.  MBL treated mice has expression 
level of IL6 like normal mice while PBS control group have significantly higher IL6 
expression level (P < 0.05) 
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Figure 41: IL12 expression.  MBL treated mice had lower expression 
level of IL12 than normal and PBS group however statistically 
insignificant. 
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Discussion 
Psoriasis, an inflammatory proliferative skin condition, is multifactorial in nature with 
no obvious single etiology. It is accepted that psoriasis pathogenesis involves, in 
genetically susceptible individuals, a dysregulated innate and adaptive immune response 
to an unknown antigen (Brotas et al., 2012; Burden and Kirby, 2016; Coimbra et al., 
2012; Lee et al., 2012; Mahil et al., 2016; Mitra et al., 2013). 
In vivo studies are essential for understanding the mechanisms of psoriasis 
development and testing different therapeutics. Only human develops psoriasis 
spontaneously with only two reports in monkeys (Swindell et al., 2011). This need for in 
vivo model of psoriasis, closely resemble the actual process takes place in human, urged 
scientists to develop models for psoriasis development. Because of the multifactorial 
nature of the disease - genetic background, different immune dysregulation, vascular 
phenomenon, keratinocyte abnormal hyperproliferation - different models were 
developed. Each model tries to focus on a certain dysregulation in the pathway of 
psoriasis development (Gudjonsson et al., 2007; Swindell et al., 2011). Animal models 
of psoriasis include endothelial- specific receptor tyrosine kinase overexpression in basal 
keratinocytes (KCs) (K5-Tie2), the human amphiregulin overexpression in the basal 
epidermal layer (K14-AREG), basal KC-specific constitutively active mutant of signal 
transducer and activator of transcription 3 overexpression (K5-Stat3C), the latent form of 
transforming growth factor beta 1 overexpression in basal KCs (K5-TGFβ1) (Swindell et 
al., 2011), The vascular endothelial growth factor overexpression in basal keratinocyte 
(K14-VEGF) (Kang et al., 2016), a xenograft model with  human lesional or non lesional 
psoriatic skin get transplanted into severe combined immune deficiency mouse 
(Gudjonsson et al., 2007), intradermal IL-23 injected mouse (Jiang et al., 2013) and 
imiquimod mouse model of psoriasis (Van der Fits et al., 2009).  
For a psoriasis mouse model to be ideal, it should show well recognizable epidermal 
hyperproliferation, thickening with altered differentiation of the epidermis, an 
inflammatory infiltrate that includes T- cells and dendritic cells, altered cutaneous 
vascularity, and responsiveness to current antipsoriatic therapeutics (Swindell et al., 
2011).  
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Having different options to choose from, the point investigated in the pathway of 
psoriasis development will direct the choice of optimal mouse model. K5-Stat3C and 
K14-AREG specifically address the abnormal keratinocyte homeostasis in psoriasis 
pathogenesis. While K5-TGFβ1 & K5-Tie2 add to addressing the abnormal keratinocyte 
homeostasis abnormal vascular phenomena, oxidative stress and basement membrane 
degradation. K14-VEGF model address the vascular phenomena of psoriasis and the 
STAT3 pathway since it signals through it (Gudjonsson et al., 2007; Swindell et al., 
2011). The best models mainly address the immune dysregulation are IL-23 & 
Imiquimod induction models. IL23 is a central key cytokine in psoriasis development 
induces with IL6 the differentiation of Th17 cells a central cell in psoriasis pathogenesis 
(Jiang et al., 2013). However this model doesn’t address the early steps in psoriasis 
pathogenesis involving dendritic cell activation and TLR role in psoriasis. IL23- model of 
psoriasis is a promising yet quite recent model with little work done on it in the literature.  
Imiquimod, 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine, is an immune 
response modifier known for its antiviral and antitumor effects. It is an FDA approved 
therapy for anogenital warts, actinic keratosis, and superficial basal cell carcinomas. The 
induction or exacerbation of psoriasis is a known side effect for Imiquimod use (Hanna 
et al., 2016). Van der Fits and coworkers were first to use Imiquimod in the induction of 
psoriasis in mice in 2009 (Van der Fits et al., 2009). The induced lesions were clinically 
and histopathologically very similar to psoriasis and on molecular basis it was mediated 
by IL17/23 pathway activation (Van der Fits et al., 2009). The known effects of 
Imiquimod explain its success in inducing psoriasis. Imiquimod is TLR7/8 agonist 
recruiting pDCs, activating NFκB and inducing the secretion of several cytokines 
including, IFN-α, TNF-α, IL-1, IL-1RA, IL-6, IL-8, IL-12 among others (Hanna et al., 
2016). Being well-established model since 2009, Imiquimod psoriasis model has been 
utilized in a lot of publication addressing the pathogenesis and therapeutics of psoriasis 
(Callahan et al., 2013; Chamcheu et al., 2017; Lai et al., 2015; van der Fits et al., 
2009; Zanvit et al., 2015) For all these reasons we decided to use Imiquimod induced 
psoriasis model for assessment of the efficacy of MBL in treatment of psoriasis. 
We successfully induced psoriasiform lesions in the back skin of C57Bl female mice. 
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The clinical examination showed significant increase in the erythema scaling and 
thickness between normal and 6 days imiquimod groups, (Figure 25)  (P = 0.001). 
To our knowledge this is the first time dermoscopy is used in experimental 
dermatology for psoriasis animal model induction and follow up of therapeutic response. 
In human, psoriasis dermoscopic criteria include homogenous background erythema with 
homogenously distributed dotted vessels along with white silvery scales (Lallas et al., 
2012; Micali et al., 2011). Imiquimod induced psoriasiform lesions showed dermoscopic 
criteria of psoriasis seen in human, (Figure 26). For the assessment of treatment response 
we developed a scoring system for the degree of background erythema, dotted vessels 
and silvery scaling graduated from 0 = normal, 1= mild, 2= moderate and 3= sever, 
(Figures 17 - 24). Using dermoscopy has aided the clinical score and made it more 
precise specifically in erythema assessment. Successful psoriasis induction was proved 
histologically with cardinal features of psoriasis detected as hyperkeratosis, acanthosis 
(increased epidermal thickness, P = 0.001), parakeratosis and inflammatory infiltrate of 
the skin (Figure 27). 
On successful induction of psoriasis, we evaluated the efficacy of MBL in psoriasis 
treatment. To understand psoriasis development, it is important to take in consideration 
that to maintain skin homeostasis, there is a balance between proinflammatory state, 
which is needed as a protective immune response when skin is preached, and the anti-
inflammatory state to fine tune the immune response to avoid exaggerated immune 
response leading to tissue damage (Miller et al., 2005). The dysregulation of such 
mechanisms ends up in abnormal continuous inflammatory response as seen in psoriasis.   
Mannose binding lectin is a pattern recognition molecule, involved in innate immune 
response against microorganisms, apoptotic cells as well as the modulation of 
inflammatory response (Dommett et al., 2006; Takahashi, 2011). It is a serum protein, 
synthesized and secreted mainly by liver. MBL is an acute phase reactant, its production 
is enhanced by inflammatory stimuli and is recruited from blood stream to sites of 
inflammation (Tsutsumi et al., 2006). Functional MBL presents in the serum as 
multimers. Trimmers, and tetramers are the most common functional forms (Dommett et 
al., 2006; Takahashi, 2011). 
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MBL acts as an immune response regulator with an anti-inflammatory activity 
protecting the body against excessive, unneeded, immune responses that would cause 
excess tissue damage (Downing et al., 2003; Downing et al., 2005; Wang et al., 2011a). 
Based on the known literature, MBL can play a role in psoriasis development through 
its immune modulatory function. MBL binds to monocytes and other immune cells at 
inflammatory loci (Downing et al., 2005). At high concentration, MBL directly binds to 
and inhibits the LPS induced maturation of immature moDCs and consequently MBL 
significantly inhibits LPS-induced TNF-α and IL-12 production from mature moDcs and 
subsequent T cell activation and proliferation (Wang et al., 2011b) MBL binds to TLR4 
of monocytes inhibiting LPS induced NF-κB pathway activation and cytokine release 
(TNFα & IL12). This interaction between MBL and TLR4 functions as a safeguard 
against excess damage of the body in inflammatory conditions (LPS tolerance) (Wang et 
al., 2011a). In monocytes also, MBL inhibits CpG induced TLR9 signaling and TNFα & 
IL-6 secretion (Tang et al., 2015). MBL inhibits double stranded RNA mediated TLR3 
signaling in monocytes and subsequent IL-6 & TNF-α secretion (Liu et al., 2014). TLR3 
has been recently associated with keratinocyte expression of the shared p40 subunit of 
IL23 & IL12 (Ramnath et al., 2015). MBL null mice died of cytokine storm resulted in 
septic shock when infected with S. aureus infection (Nadesalingam et al., 2005). 
Interestingly MBL role in cutaneous inflammatory response to injury was addressed in 
MBL null mice subjected to burn (thermal injury). The MBL null mice showed abnormal 
response with reduced sloughing of eschar (dead skin) and interestingly abnormal 
epidermal acanthosis compared to wild type mice (Moller-Kristensen et al., 2007; 
Takahashi, 2011). Antagonists of TLRs - anti TLR7, 8 & 9 - showed efficacy in 
psoriasis management (Jiang et al., 2013). Monomethyl fumarate, an immunotherapy for 
psoriasis, inhibits NF-κB activation, decreases IL-12 production, and modulates moDCs 
polarization through interfering with LPS induced TLR4 signaling in dendritic cells. In 
other words monomethyl fumarate, a therapeutic of psoriasis, has the same effect of MBL 
on LPS induced TLR4 signaling pathway as proved by Wang and coworkers (Hari et al., 
2010; Wang et al., 2011a). Retinoids, another effective therapeutic for psoriasis, exerts 
their anti-inflammatory & immunomodulatory activity through inhibition of TLR4/ 
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NFκB signaling blocking various cytokine secretion including IL1β, IL 6, IL12 and TNF-
α (Kim et al., 2013; Gu et al., 2010). Ultraviolet B (UVB), phototherapy of psoriasis, 
recruits MBL to the skin (Lokitz et al., 2005). In Turkish population, the B allel of mbl 
gene is more frequent in psoriatics than normal (Turan et al., 2014). Although this 
wasn’t proved in Egyptian population yet psoriatic patients with homozygous AA or 
heterozygous AB genotypes have better response to therapy than homozygous BB 
genotype. Patients with AB & BB genotypes responded well to Red Sea climatotherapy, 
albeit temporarily which can be attributed to MBL recruitment to skin on UVB exposure 
on Safaga climatotherapy (Nofal, 2014). Thus we hypothesize that MBL can be an 
effective therapeutic in treatment of psoriasis especially that it targets an early step in 
psoriasis pathogenesis. 
In our work the induced psoriasiform lesions were successfully treated by intradermal 
injection of recombinant mouse MBL (3 µg/ day for 4 consecutive days). The reversal of 
psoriasiform lesions was evident clinically (P < 0.05) (Figures 29, 30, 31 & 32), 
dermoscopically (P= 0.045)  (Figure 33 & 34), skin fold thickness (Figure 32), 
epidermal thickness on histopathological assessment (Figure 35 & 36).  
MBL treated mice gained weight on MBL treatment while the control group received 
only PBS continued to express psoriasiform lesions and to loose weight (Figure 28). 
The areas distant to the site of injection showed also improvement like the injected 
areas (Figure 37, Table 13, 14 & 15).  
The spleen histopathology of PBS control group showed expansion of the white pulp 
indicating an immune reactivation process, however the spleen of MBL treated mice was 
of normal histology (Figure 38). The weight of spleen of MBL & PBS groups was 
significantly higher than normal spleen. Yet, splenic weight didn’t differ significantly in 
between both groups. This can be attributed to the anti-inflammatory effect of MBL 
reversing the immune reactivation process with normal splenic histopathology yet the 
weight wasn’t reduced either due to enlarged connective tissue stroma of the spleen or 
due to the weight gain of MBL treated mice to which splenic weight correlates.  
The improvement of distant areas of skin and of the histopathologic features of spleen 
indicate that the used dose of MBL exerted systemic effect which raise the possibility of 
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using smaller doses in future studies.   
 MBL is a TLR4, 9 and 3 antagonist blocking NFκB activation with subsequent 
reduction of several cytokine secretion as TNFα, IL-6, IL-12. IL-6 and IL-12 are key 
early players in psoriasis development. IL-6 plays central role in the establishment and 
maintenance of Th17 profile. IL-12 establishes the production of IFN-γ from Th-1 cells 
early in psoriasis development. We tried to identify the possible down stream targets of 
MBL. As expected MBL treatment reduced IL-6 expression in MBL treated group back 
to normal level while its expression was significantly higher in PBS group (Figure 40). 
IL 12 expression didn’t differ between PBS control group and normal (Figure 41) 
indicting that imiquimod doesn’t alter IL12 expression profile. IL12 expression profile 
was reduced in MBL treated group compared to its production in both normal and PBS 
control group, albeit statistically insignificant, such observation indicates that MBL 
reduced the IL12 below normal levels so in human psoriasis MBL can play role through 
blocking IL12 as in Ustekinumab, a monoclonal antibody against shared p40 subunit of 
IL23 & IL12, used for psoriasis therapy. 
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Conclusions & Recommendations: 
 
In conclusion, Imiquimod animal model of psoriasis is a representative and feasible 
model for early immune mediated psoriasis pathway. MBL represent a promising 
therapeutic for psoriasis, being an immune response modulator secreted at the site of 
inflammation to safeguard against excessive unneeded tissue damage. MBL targets many 
steps in psoriasis pathway including early steps of antigen presentation via TLRs and 
dendritic cell maturation. MBL dependent reversal of psoriasiform lesions induced by 
Imiquimod is associated with reduction of IL-6 expression and to some extent to IL12.  
 
We recommend more studies to identify the efficacy of MBL in preventing the 
development of psoriasis lesions and to evaluate the efficacy of MBL in treating 
psoriasiform lesions in other animal models e.g. IL23 induced psoriasis model. 
Modification of the dose can be done to identify the least effective dose. Clinical trials of 
MBL treatment in psoriatic patients either as systemic therapy or intra-lesional can be 
started given the availability of MBL which has been successfully extracted from human 
plasma and used for clinical trials in chemotherapy patients (Table 1). Nanotechnology 
aided MBL delivery may enhance the delivery and decrease the dose of recombinant 
human MBL.   
 
	  	  
	   References	  	  
	   	  
88 	  
REFERENCES: 
Akira S, Takeda K. (2004). Toll-like receptor signalling. Nat Rev Immunol. 4: 499-511. 
Albanesi C, Scarponi C, Bosisio D, et al. (2010).  Immune functions and recruitment of 
plasmacytoid dendritic cells in psoriasis Autoimmunity. 43: 215-9. 
Ariza ME, Williams MV, Wong HK. (2013). Targeting IL-17 in psoriasis: from 
cutaneous immunobiology to clinical application. Clin. Immunol. 146: 131-9. 
Baker BS, Ovigne JM, Powles AV, et al. (2003). Normal keratinocytes express Toll-
like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic 
plaque psoriasis. Br J Dermatol. 148: 670-9. Quoted from Garcia-Rodriguez et 
al., 2013. 
Baliwag, J., Barnes, D. H., & Johnston, A. (2015). Cytokines in psoriasis. Cytokine, 
73(2), 342-350. 
Bang, P., Laursen, I., Thornberg, K., Schierbeck, J., Nielsen, B., Valdimarsson, H., 
... & Christiansen, M. (2008). The pharmacokinetic profile of plasma-derived 
mannan-binding lectin in healthy adult volunteers and patients with 
Staphylococcus aureus septicaemia. Scandinavian journal of infectious diseases, 
40(1), 44-48. 
Bayram N, Ozkinay F, Onay H, et al. (2012). Mannose-binding lectin gene codon 54 
polymorphism susceptible to brucellosis in Turkish children. Turk J Pediatr. 54: 
234-8. 
Bergman IM. (2011). Toll-like receptors (TLRs) and mannan-binding lectin (MBL): on 
constant alert in a hostile environment. Ups J Med Sci. 116: 90-9. 
Brotas AM, Cunha JM, Lago EH, et al. (2012). Tumor necrosis factor-alpha and the 
cytokine network in psoriasis. An Bras Dermatol. 87:673-81 
Brouwer N, Frakking FN, van de Wetering MD, et al. (2009). Mannose-binding lectin 
(MBL) substitution: recovery of opsonic function in vivo lags behind MBL 
serum levels. J Immunol. 18: 3496-504. 
	  	  
	   References	  	  
	   	  
89 	  
Burden, A. D. and Kirby, B. 2016. Psoriasis and Related Disorders. Rook's Textbook of 
Dermatology, Ninth Edition. 1–64. 
Büchau AS, Gallo RL. (2007). Innate immunity and antimicrobial defense systems in 
psoriasis. Clin Dermatol. 25: 616-24. 
Callahan, J. A., Hammer, G. E., Agelides, A., Duong, B. H., Oshima, S., North, J., ... 
& Barrera, J. (2013). Cutting edge: ABIN-1 protects against psoriasis by 
restricting MyD88 signals in dendritic cells. The Journal of Immunology, 
191(2), 535-539. 
Chamcheu, J. C., Adhami, V. M., Esnault, S., Sechi, M., Siddiqui, I. A., Satyshur, K. 
A., ... & Wood, G. S. (2017). Dual Inhibition of PI3K/Akt and mTOR by the 
Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in 
an Imiquimod-Induced Psoriasis-Like Disease in Mice. Antioxidants & redox 
signaling, 26(2), 49-69. 
Cai Y, Fleming C, Yan J. (2013). Dermal γδ T cells - A new player in the pathogenesis 
of psoriasis. Int Immunopharmacol. 16: 388-91. 
Coimbra S, Figueiredo A, Castro E, et al. (2012).  The roles of cells and cytokines in 
the pathogenesis of psoriasis.	  Int J Dermatol. 51: 389-95. 
Connolly DJ, O'Neill LA. (2012). New developments in Toll-like receptor targeted 
therapeutics.	  Curr Opin Pharmacol. 12: 510-8. 
De Messias-Reason IJ, Boldt AB, Moraes Braga AC, et al. (2007). The association 
between mannan-binding lectin gene polymorphism and clinical leprosy: new 
insight into an old paradigm. J Infect Dis. 196: 1379-85. 
Denadai R. (2013). The role of plasmacytoid dendritic cells and interferon-alpha in the 
immunopathogenesis of psoriasis. Indian J Dermatol. 58: 247- 247 
Dommett RM, Klein N, Turner MW. (2006). Mannose-binding lectin in innate 
immunity: Past, present and future. Tissue Antigens. 68: 193 - 209. 
Downing I, Koch C, Kilpatrick DC. (2003). Immature dendritic cells possess a sugar-
sensitive receptor for human mannan-binding lectin. Immunology. 109: 360-4. 
	  	  
	   References	  	  
	   	  
90 	  
Downing I, MacDonald SL, Turner ML, et al. (2005). Detection of an autologous 
ligand for mannan-binding lectin on human B lymphocytes.	  Scand J Immunol. 
62: 507-14.    
Duus K, Thielens NM, Lacroix M, et al. (2010). CD91 interacts with mannan-binding 
lectin (MBL) through the MBL-associated serine protease-binding site. FEBS J. 
277: 4956-64. 
Fantuzzi G, Reed DA, Dinarello CA. (1999). IL-12-induced IFN-gamma is dependent 
on caspase-1 processing of the IL-18 precursor. J Clin Invest. 104: 761-7. 
Farkas A, Kemény L. (2012). Monocyte-derived interferon-alpha primed dendritic cells 
in the pathogenesis of psoriasis: new pieces in the puzzle. Int 
Immunopharmacol. 13: 215-8. 
Fitch, E., Harper, E., Skorcheva, I., Kurtz, S. E., & Blauvelt, A. (2007). 
Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. 
Current rheumatology reports, 9(6), 461-467. 
Flyvbjerg A. (2010).  Diabetic angiopathy, the complement system and the tumor 
necrosis factor superfamily. Nat Rev Endocrinol. 6: 94-101. 
Frakking FN, Brouwer N, van de Wetering MD, et al. (2009). Safety and 
pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution 
in children with chemotherapy-induced neutropaenia.  Eur J Cancer. 45:505-12. 
Quoted from Heitzeneder et al., 2012. 
Fredriksson T, Pettersson U. (1978). Severe psoriasis--oral therapy with a new retinoid. 
Dermatologica. 157:238-44. Quoted from Warren et al., 2009. 
Fujita H. (2013). The role of IL-22 and Th22 cells in human skin diseases. J Dermatol 
Sci. 72: 3-8. 
Garcia-Rodriguez S, Arias-Santiago S, Perandrés-López R, et al. (2013). Increased 
gene expression of Toll-like receptor 4 on peripheral blood mononuclear cells in 
patients with psoriasis. J Eur Acad Dermatol Venereol. 27:242-50. 
	  	  
	   References	  	  
	   	  
91 	  
Garred, P., Pressler, T., Lanng, S., Madsen, H. O., Moser, C., Laursen, I., ... & 
Koch, C. (2002). Mannose-­‐‑binding lectin (MBL) therapy in an MBL-­‐‑deficient 
patient with severe cystic fibrosis lung disease. Pediatric pulmonology, 33(3), 
201-207. 
Gaspari AA. (2006). Innate and adaptive immunity and the pathophysiology of psoriasis. 
J Am Acad Dermatol. 54: S67-80. 
Girolomoni G, Mrowietz U, Paul C. (2012). Psoriasis: rationale for targeting 
interleukin-17. Br J Dermatol. 167: 717-24. 
Griffiths C.E.M. & Barker J.N.W.N. (2010). Psoriasis. In: Rook’s Textbook of 
Dermatology. (Burns T, Breathnach S, Cox N, Griffiths C, eds), 8th ed. Oxford, 
UK: Wiley-Blackwell, 871-930. 
Gu, B., Miao, J., Fa, Y., Lu, J., & Zou, S. (2010). Retinoic acid attenuates 
lipopolysaccharide-induced inflammatory responses by suppressing TLR4/NF-
κB expression in rat mammary tissue. International immunopharmacology, 
10(7), 799-805. 
Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H., & Elder, J. T. (2007). 
Mouse models of psoriasis. The Journal of investigative dermatology, 127(6), 
1292. 
Hari A, Flach TL, Shi Y, et al. (2010). Toll-like receptors: role in dermatological 
disease. Mediators Inflamm. 2010: 1-16. 
Hanna, E., Abadi, R., & Abbas, O. (2016). Imiquimod in dermatology: an overview. 
International journal of dermatology, 55(8), 831-844. 
Hébert HL, Ali FR, Bowes J, et al. (2012). Genetic susceptibility to psoriasis and 
psoriatic arthritis: implications for therapy. Br J Dermatol. 166: 474-82.  
Heitzeneder S, Seidel M, Förster-Waldl E, et al. (2012). Mannan-binding lectin 
deficiency-Good news, bad news, doesn't matter? Clin Immunol.143: 22-38. 
Hollox EJ, Huffmeier U, Zeeuwen PL, et al. (2008). Psoriasis is associated with 
increased beta-defensin genomic copy number. Nat Genet. 40: 23-5.  
	  	  
	   References	  	  
	   	  
92 	  
Ip WK, Takahashi K, Moore KJ, et al. (2008). Mannose-binding lectin enhances Toll-
like receptors 2 and 6 signaling from the phagosome. J Exp Med. 205: 169-81. 
Ivanov II, McKenzie BS, Zhou L, et al. (2006). The orphan nuclear receptor ROR 
gammat directs the differentiation program of proinflammatory IL-17+ T helper 
cells. Cell. 126: 1121 - 33. 
Jack DL, Klein NJ, Turner MW. (2001). Mannose-binding lectin: Targeting the 
microbial world for complement attack and opsonophagocytosis. Immunol Rev. 
180: 86-99. 
Jiang W, Zhu FG, Bhagat L, et al. (2013). Toll-Like Receptor 7, 8, and 9 Antagonist 
Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of 
IL-23-Induced Psoriasis. J Invest Dermatol. 133: 1777-84. 
Jiaravuthisan MM, Sasseville D, Vender RB, et al. (2007). 	   Psoriasis of the nail: 
anatomy, pathology, clinical presentation, and a review of the literature on 
therapy. J Am Acad Dermatol. 57: 1-27.  
Kagami S, Rizzo HL, Lee JJ, et al. (2010). Circulating Th17, Th22, and Th1 cells are 
increased in psoriasis. J Invest Dermatol. 130: 1373-83. 
Kang, D., Li, B., Luo, L., Jiang, W., Lu, Q., Rong, M., & Lai, R. (2016). Curcumin 
shows excellent therapeutic effect on psoriasis in mouse model. Biochimie, 123, 
73-80. 
Kim, S. Y., Koo, J. E., Song, M. R., & Lee, J. Y. (2013). Retinol suppresses the 
activation of Toll-like receptors in MyD88-and STAT1-independent manners. 
Inflammation, 36(2), 426-433. 
Kim, J., Nadella, P., Kim, D. J., Brodmerkel, C., da Rosa, J. C., Krueger, J. G., & 
Suárez-Fariñas, M. (2015). Histological stratification of thick and thin plaque 
psoriasis explores molecular phenotypes with clinical implications. PloS one, 
10(7), e0132454. 
Kupetsky EA, Mathers AR, Ferris LK. (2013).  Anti-cytokine therapy in the treatment 
of psoriasis. Cytokine. 61: 704-12. 
	  	  
	   References	  	  
	   	  
93 	  
Laggner U, Di Meglio P, Perera GK, et al. (2011).  Identification of a novel 
proinflammatory human skin-homing Vγ9Vδ2 T cell subset with a potential role 
in psoriasis. J Immunol. 187: 2783-93. 
Lallas, A., Kyrgidis, A., Tzellos, T. G., Apalla, Z., Karakyriou, E., Karatolias, A., ... 
& Zalaudek, I. (2012). Accuracy of dermoscopic criteria for the diagnosis of 
psoriasis, dermatitis, lichen planus and pityriasis rosea. British Journal of 
Dermatology, 166(6), 1198-1205. 
Lai, C. Y., Yeh, D. W., Lu, C. H., Liu, Y. L., Huang, L. R., Kao, C. Y., ... & Xiang, 
R. (2015). Identification of Thiostrepton as a Novel Inhibitor for Psoriasis-like 
Inflammation Induced by TLR7–9. The Journal of Immunology, 195(8), 3912-
3921. 
Lande R, Gregorio J, Facchinetti V, et al. (2007). Plasmacytoid dendritic cells sense 
self-DNA coupled with antimicrobial peptide. Nature. 449: 564-9. 
Lee C, Hwang S. (2012).  Pathophysiology of chemokines and chemokine receptors in 
dermatological science: A focus on psoriasis and cutaneous T-cell lymphoma. 
Dermatologica Sinica. 30: 128-135. 
Lever, W. F. & Elder, D. E. (2009). Lever's histopathology of the skin (10th ed.). 
Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 
Li, D., Dong, B., Tong, Z., Wang, Q., Liu, W., Wang, Y., ... & Duan, Y. (2012). MBL-
Mediated Opsonophagocytosis of Candida albicans by Human Neutrophils Is 
Coupled with Intracellular Dectin-1-Triggered ROS Production. PLoS ONE, 
7(12). 
Liu, H., Zhou, J., Ma, D., Lu, X., Ming, S., Shan, G., ... & Zuo, D. (2014). Mannan 
binding lectin attenuates double-stranded RNA-mediated TLR3 activation and 
innate immunity. FEBS letters, 588(6), 866. 
Lokitz M, Zhang W, Bashir M. (2005). Ultraviolet-B Recruits Mannose-Binding Lectin 
into Skin from Non-Cutaneous Sources. J Invest Dermatol. 125:166-73. 
	  	  
	   References	  	  
	   	  
94 	  
MacDonald SL, Downing I, Atkinson AP, et al. (2010). Dendritic cells previously 
exposed to mannan-binding lectin enhance cytokine production in allogeneic 
mononuclear cell cultures. Hum Immunol. 71: 1077-83. 
Mahil, S. K., Capon, F., & Barker, J. N. (2016). Update on psoriasis 
immunopathogenesis and targeted immunotherapy. In Seminars in 
immunopathology. 38: 11-27. 
Mathur AN, Chang HC, Zisoulis DG, et al. (2007). Stat3 and Stat4 direct development 
of IL-17-secreting Th cells. J Immunol. 178: 4901 - 7. 
Micali, G., Lacarrubba, F., Massimino, D., & Schwartz, R. A. (2011). Dermatoscopy: 
alternative uses in daily clinical practice. Journal of the American Academy of 
Dermatology, 64(6), 1135-1146. 
Michelow, I. C., Lear, C., Scully, C., Prugar, L. I., Longley, C. B., Yantosca, L. M., 
... & Spear, G. T. (2011). High-dose mannose-binding lectin therapy for Ebola 
virus infection. Journal of Infectious Diseases, 203(2), 175-179. 
Miller LS, Sørensen OE, Liu PT, et al. (2005). TGF-alpha regulates TLR expression 
and function on epidermal keratinocytes. J Immunol. 174: 6137-43. 
Mitra A, Fallen RS, Lima HC. (2013). Cytokine-based therapy in psoriasis. Clin Rev 
Allergy Immunol. 44: 173-82. 
Mizutani H, Ohmoto Y, Mizutani T, et al. (1997). Role of increased production of 
monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal 
infection, disease activity and responses to treatments.	  	  J Dermatol Sci. 14: 145-
53. Quoted from Turan et al., 2014. 
Morizane, S., Yamasaki, K., Mühleisen, B., Kotol, P. F., Murakami, M., Aoyama, 
Y., ... & Gallo, R. L. (2012). Cathelicidin antimicrobial peptide LL-37 in 
psoriasis enables keratinocyte reactivity against TLR9 ligands. Journal of 
Investigative Dermatology, 132(1), 135-143. 
	  	  
	   References	  	  
	   	  
95 	  
Møller-Kristensen M, Hamblin MR, Thiel S, et al. (2007).  Burn injury reveals altered 
phenotype in mannan-binding lectin-deficient mice. J Invest Dermatol. 127: 
1524-31. 
Møller-Kristensen, M., Ip, W. E., Shi, L., Gowda, L. D., Hamblin, M. R., Thiel, S., ... 
& Takahashi, K. (2006). Deficiency of mannose-binding lectin greatly 
increases susceptibility to postburn infection with Pseudomonas aeruginosa. The 
Journal of Immunology, 176(3), 1769-1775. 
Nadesalingam J, Dodds AW, Reid KB, et al. (2005). Mannose-binding lectin 
recognizes peptidoglycan via the N-acetyl glucosamine moiety, and inhibits 
ligand-induced proinflammatory effect and promotes chemokine production by 
macrophages. J Immunol.  175: 1785 - 94. 
Nestle FO, Conrad C, Tun-Kyi A, et al. (2005). Plasmacytoid predendritic cells initiate 
psoriasis through interferon-alpha production. J Exp Med. 202: 135 - 43. 
Nestle FO, Kaplan DH, Barker J.	  (2009). Psoriasis. N Engl J Med. 361: 496-509. 
Nestle FO, Turka L a, Nickoloff BJ. (1994). Characterization of dermal dendritic cells 
in psoriasis. Auto stimulation of T lymphocytes and induction of Th1 type 
cytokines. J Clin Invest. 94: 202-9. 
Nofal, H (2014). Mannose binding Lectin gene polymorphism in psoriatic patients 
(Master’s thesis). Retrieved from Faculty of Medicine library, Zagazig 
university. 
Nograles KE, Zaba LC, Shemer A, et al. (2009). IL-22-producing "T22" T cells 
account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-
producing TH17 T cells. J Allergy Clin Immunol. 123: 1244-52. 
Nomura I, Goleva E, Howell MD, et al. (2003). Cytokine milieu of atopic dermatitis, as 
compared to psoriasis, skin prevents induction of innate immune response 
genes. J Immunol. 171: 3262-9. 
Ono K, Nishitani C, Mitsuzawa H, et al. (2006). Mannose-binding lectin augments the 
uptake of lipid A, Staphylococcus aureus, and Escherichia coli by Kupffer cells 
	  	  
	   References	  	  
	   	  
96 	  
through increased cell surface expression of scavenger receptor A. J Immunol. 
177: 5517-23. 
Ozawa A, Ohkido M, Haruki Y, et al. (1999). Treatments of generalized pustular 
psoriasis: a multicenter study in Japan. J Dermatol. 26: 141-9. Quoted from 
Sigurdardottir et al., 2013. 
Pandey S, Agrawal DK. (2006). Immunobiology of Toll-like receptors: emerging 
trends. Immunol Cell Biol. 84: 333-41.  
Parker LC, Prince LR, Sabroe I. (2007). Translational mini-review series on toll-like 
receptors: Networks regulated by toll-like receptors mediate innate and adaptive 
immunity. Clin Exp Immunol. 147: 199-207. 
Pasare C, Medzhitov R. (2004). Toll-like receptors and acquired immunity. Semin 
Immunol. 16: 23-26. 
Peric M, Koglin S, Dombrowski Y, et al. (2009). Vitamin D analogs differentially 
control antimicrobial peptide/"alarmin" expression in psoriasis. PLoS One. 4: 1-
10. 
Petersen, K. A., Matthiesen, F., Agger, T., Kongerslev, L., Thiel, S., Cornelissen, K., 
& Axelsen, M. (2006). Phase I safety, tolerability, and pharmacokinetic study 
of recombinant human mannan-binding lectin. Journal of clinical immunology, 
26(5), 465-475. 
Pollock R, Chandran V, Barrett J, et al. (2011). Differential major histocompatibility 
complex class I chain-related A allele associations with skin and joint 
manifestations of psoriatic disease. Tissue Antigens. 77: 554-61. 
Prignano F, Ricceri F, Beccatti M, et al. (2012). Circulating dendritic cell subsets in 
psoriatic patients before and after biologic therapy. J Dermatol. 39: 274-5. 
Ram, S., Lewis, L. A., & Rice, P. A. (2010). Infections of people with complement 
deficiencies and patients who have undergone splenectomy. Clinical 
microbiology reviews, 23(4), 740-780. 
	  	  
	   References	  	  
	   	  
97 	  
Ramnath, D., Tunny, K., Hohenhaus, D. M., Pitts, C. M., Bergot, A. S., Hogarth, P. 
M., ... & Sweet, M. J. (2015). TLR3 drives IRF6-dependent IL-23p19 
expression and p19/EBI3 heterodimer formation in keratinocytes. Immunology 
and cell biology, 93(9), 771-779. 
Reinholz M, Ruzicka T, Schauber J. (2012). Cathelicidin LL-37: an antimicrobial 
peptide with a role in inflammatory skin disease. Ann Dermatol. 24: 126-35. 
Rizzo HL, Kagami S, Phillips KG, et al. (2011). IL-23-mediated psoriasis-like 
epidermal hyperplasia is dependent on IL-17A. J Immunol. 186: 1495-502. 
Sabat, R., Philipp, S., Höflich, C., Kreutzer, S., Wallace, E., Asadullah, K., ... & 
Wolk, K. (2007). Immunopathogenesis of psoriasis. Experimental dermatology, 
16(10), 779-798. 
Saggini, A., Chimenti, S., & Chiricozzi, A. (2014). IL-6 as a druggable target in 
psoriasis: focus on pustular variants. Journal of immunology research, 2014. 
Seung NR, Park EJ, Kim CW, et al. (2007). Comparison of expression of heat-shock 
protein 60, Toll-like receptors 2 and 4, and T-cell receptor gamma delta in 
plaque and guttate psoriasis. J Cutan Pathol. 34: 903-11. Quoted from Garcia-
Rodriguez et al., 2013. 
Shi, L., Takahashi, K., Dundee, J., Shahroor-Karni, S., Thiel, S., Jensenius, J. C., ... 
& Ezekowitz, R. A. B. (2004). Mannose-binding lectin-deficient mice are 
susceptible to infection with Staphylococcus aureus. The Journal of 
experimental medicine, 199(10), 1379-1390. 
Shimizu T, Nishitani C, Mitsuzawa H, et al. (2009). Mannose binding lectin and lung 
collectins interact with Toll-like receptor 4 and MD-2 by different mechanisms. 
Biochim Biophys Acta. 1790:1705-10. 
Shinya K, Ito M, Makino A, et al. (2012). The TLR4-TRIF pathway protects against 
H5N1 influenza virus infection. J Virol. 86: 19-24. 
	  	  
	   References	  	  
	   	  
98 	  
Sigurdardottir SL, Thorleifsdottir RH, Valdimarsson H, et al. (2013).  The role of the 
palatine tonsils in the pathogenesis and treatment of psoriasis.	  Br J Dermatol. 
168: 237-42. 
Steinman RM, Idoyaga J. (2010). Features of the dendritic cell lineage. Immunol Rev. 
234: 5-17. 
Sticherling M. (2005).  Mechanisms of psoriasis. Drug Discovery Today: Disease 
Mechanisms. 2: 275-281. 
Strange A, Capon F, Spencer CC, et al. (2010). A genome-wide association study 
identifies new psoriasis susceptibility loci and an interaction between HLA-C 
and ERAP1.	  Nat Genet.42: 985-90. 
Stuart PE, Hüffmeier U, Nair RP, et al. (2012). Association of β-defensin copy number 
and psoriasis in three cohorts of European origin. J Invest Dermatol. 132: 2407-
13. 
Swindell, W. R., Johnston, A., Carbajal, S., Han, G., Wohn, C., Lu, J., ... & Wang, 
X. J. (2011). Genome-wide expression profiling of five mouse models identifies 
similarities and differences with human psoriasis. PloS one, 6(4), e18266. 
Tang, Y., Ma, D., Ming, S., Zhang, L., Zhou, J., Shan, G., ... & Zuo, D. (2015). 
Mannan-binding lectin reduces CpG DNA-induced inflammatory cytokine 
production by human monocytes. Microbiology and immunology, 59(4), 231. 
Takahashi K. (2011).  Mannose-binding lectin and the balance between immune 
protection and complication. Expert Rev Anti Infect Ther. 9: 1179-90. 
Tenaud I, Khammari A, Dreno B. (2007). In vitro modulation of TLR-2, CD1d and IL-
10 by adapalene on normal human skin and acne inflammatory lesions. Exp 
Dermatol. 16: 500-6. Quoted from Hari et al., 2010  
Tohyama M, Yang L, Hanakawa Y, et al. (2012). IFN-α enhances IL-22 receptor 
expression in keratinocytes: a possible role in the development of psoriasis. J 
Invest Dermatol. 132: 1933-5. 
	  	  
	   References	  	  
	   	  
99 	  
Tsutsumi A, Takahashi R, Sumida T. (2005). Mannose binding lectin: genetics and 
autoimmune disease. Autoimmun Rev. 4: 364-72. 
Turan H, Karkucak M, Yakut T, et al. (2014). Does MBL2 codon 54 polymorphism 
play a role in the pathogenesis of psoriasis? Int J Dermatol. 53: 34-8. 
Ueno H, Schmitt N, Klechevsky E, et al. (2010). Harnessing human dendritic cell 
subsets for medicine. Immunol Rev. 234. 199-212. 
Valdimarsson, H., Vikingsdottir, T., Bang, P., Saevarsdottir, S., Gudjonsson, J. E., 
Oskarsson, O., ... & Koch, C. (2004). Human Plasma-­‐‑Derived Mannose-­‐‑
Binding Lectin: A Phase I Safety and Pharmacokinetic Study. Scandinavian 
journal of immunology, 59(1), 97-102. 
Van der Fits, L., Mourits, S., Voerman, J. S., Kant, M., Boon, L., Laman, J. D., ... & 
Lubberts, E. (2009). Imiquimod-induced psoriasis-like skin inflammation in 
mice is mediated via the IL-23/IL-17 axis. The Journal of Immunology, 182(9), 
5836-5845. 
Wang M, Chen Y, Zhang Y, et al. (2011) a. Mannan-binding lectin directly interacts 
with Toll-like receptor 4 and suppresses lipopolysaccharide-induced 
inflammatory cytokine secretion from THP-1 cells. Cell Mol Immunol. 8: 265 - 
75. 
Wang, M., Zhang, Y., Chen, Y., Zhang, L., Lu, X., & Chen, Z. (2011) b. Mannan-
binding lectin regulates dendritic cell maturation and cytokine production 
induced by lipopolysaccharide. BMC immunology, 12(1), 1. 
World Health Organization. (2016). Global report on psoriasis. Switzerland: WHO 
Press 
Worthley DL, Bardy PG, Mullighan CG. (2005). Mannose-binding lectin: biology and 
clinical implications. Intern Med J. 35: 548-55. 
Yano S, Banno T, Walsh R, et al. (2008). Transcriptional responses of human epidermal 
keratinocytes to cytokine interleukin-1.J Cell Physiol. 214: 1-13. 
	  	  
	   References	  	  
	   	  
100 	  
Yao Y, Richman L, Morehouse C, et al. (2008). Type I interferon: potential therapeutic 
target for psoriasis? PLoS One. 3: 1-14. 
Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. (2009). Psoriasis is 
characterized by accumulation of immunostimulatory and Th1/Th17 cell-
polarizing myeloid dendritic cells. J Invest Dermatol. 129: 79-88. 
Zanvit, P., Konkel, J. E., Jiao, X., Kasagi, S., Zhang, D., Wu, R., ... & Abbatiello, B. 
(2015). Antibiotics in neonatal life increase murine susceptibility to 
experimental psoriasis. Nature communications, 6. 
Zheng Y, Caro I, Ouyang W. (2007). Role of cytokine therapy in the treatment of 
psoriasis. Drug Discov. Today Ther. Strateg. 4: 25–31. 
Zhou, Y., Lu, K., Pfefferle, S., Bertram, S., Glowacka, I., Drosten, C., ... & Simmons, 
G. (2010). A single asparagine-linked glycosylation site of the severe acute 
respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by 
mannose-binding lectin through multiple mechanisms. Journal of virology, 
84(17), 8753-8764. 
	  
	  	  
Appendices 	  
	   	  
101	  
Appendix 
Appendix 1	   	  Animal	  Psoriasis	  Sheet	  	  Animal	  Serial	  number:	  	   	   	   Type:	  	   ☐	 C57Bl	   	   ☐	 Balb	  c	  	  Specific	  Mark:	  	  Group:	  ☐	 Control	   ☐	 Treatment	  	  Induction	  schedule:	  	   Method:	  	   	   	   	   	   	   Amount:	  	  	   -­‐1	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	   13	   14	  	   Hair	  removal	   Imq	  induction	  &	  Vaseline	  control	   Imq	  +	  treatment	  &	  Imq	  +	  control	  Date	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  Notes	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  	  Samples	  collected:	  	   	  	  	  Normal   D (   ) Full Induction    D (   ) TTT 
 
☐	  RNA	  extraction	  
☐	 Formalin	  	  (w=	  	  	  	  	  	  	  	  g	  )	  
☐	 Protein	  	   ☐	  RNA	  extraction	  	  ☐	 Formalin	  	  (w=	  	  	  	  	  	  	  	  g	  )	  ☐	 Protein	   ☐	  RNA	  extraction	  	  ☐	 Formalin	  (w=	  	  	  	  	  	  	  g	  )	  	  ☐	 Protein	  
 Intervention:	  	  Type:	  ☐	 Treatment	  (MBL	  -­‐	  Curcumin)	   	   ☐	  Control	  (PBS-­‐	  Vaseline)	  	  Method/	  Amount:	  
☐	 Intra	  lesional	  	   ☐	 Topical	  	   	   ☐	 Oral/	  systemic	  	  Schedule:	  	  	   -­‐1	   0	   1	   2	   3	   4	   5	   6	   7	   8	   9	   10	   11	   12	   13	   14	  	   Hair	  removal	   Imq	  induction	  &	  Vaseline	  control	   Imq	  +	  treatment	  &	  Imq	  +	  control	  Date	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  Amount	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	   	  	  Tests	  done	  for	  the	  animal:	  
☐	  RNA	  extraction	   	   ☐Histology	   ☐Immunohistochemistry	  	   ☐Eliza	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Appendix 2:	  
Psoriasis	  Clinical	  &	  Dermoscopic	  Evaluation	  sheet:	  	  Animal	  Serial	  number:	  	   	   	   Type:	  	  ☐	 C57Bl	   	   ☐	 Balb	  c	  	  Specific	  Mark:	   	   	   	   Weight:	  	  Group:	  ☐	 Control	   ☐	 Treatment	  	  
Date:	  	   	  
	  
Day	  in	  the	  Course:	  	  ☐	 Normal	 	 	 ☐	 Mid	 induction	 	 	 ☐Full	 induction	 (	 	 )	 d	 	 	 
☐	 Mid	 treatment	 	 	 	 ☐	 Last	 treatment	 day	  	  
Clinical	  evaluation	  (Psoriasis	  Severity	  Index):	  	  Photos:	  ☐	 Y	 	 	 ☐	 N	 	 	 	 	 
	 Redness	  (0-­‐4)	  	   Thickness	  (0-­‐4)	   Scaling	  (0-­‐4)	   Total	  (0-­‐12)	  	   	   	   	  	  
Dermoscope:	  
	  	  	   Pattern/color	   Distribution	   Score	  Vessel	   	   	   	  Back	  ground	  erythema	   	   	  Scale	   	   	   	  	  
RNA	  Extraction:	  	  Date:	  (	   	   	   )	  	  OD260:	   	   	   	   	   Ratio:	  	  	   	   	   Concentration:	  	  
cDNA:	  	  Date:	  (	   	   	   )	  	  
Real	  Time	  PCR:	  Date:	  (	   	   	   )	  
	   Gene	   Expression	  Level	  	   	  	   	  	   	  	   	  	  	  
Formalin:	  	  Date	  (	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  )	   	   IHC:	  	  	  	  	  	  	  	  	  	  	  	  	  	  Date	  (	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  )	  Eliza:	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Appendix	  3:	  Copyright	  permission	  for	  Figure1:	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Appendix	  4:	  Copyright	  Permission	  for	  Figure	  2:	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Appendix	  5:	  Copyright	  permission	  for	  Figure	  3:	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Appendix	  6:	  Copyright	  permission	  for	  Figure	  4:	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Appendix	  7:	  Copyright	  permission	  For	  Figure	  5:	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Appendix	  8:	  Copyright	  permission	  for	  Figure	  6:	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Appendix	  9:	  Copyright	  permission	  for	  Figure	  7:	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Appendix	  10:	  Copyright	  permission	  for	  Figure	  8:	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Appendix	  11:	  Copyright	  permission	  for	  Figure	  9	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Appendix	  12:	  Copyright	  permission	  for	  Figure	  10:	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Appendix	  13:	  Copyright	  permission	  for	  Figure	  11:	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Appendix	  14:	  Copyright	  permission	  for	  Figure	  12:	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Appendix	  15:	  Copyright	  permission	  for	  Figure	  13	  &14:	  	  
	  	  	  
